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Zusammenfassung
Unspezifizierte periphere T-Zell-Lymphome (uPTZL) stellen eine Untergruppe der hoch
aggressiven Non-Hodgkin-Lymphome dar, die durch eine hohe Rezidivanfa¨lligkeit und eine
schlechte Langzeitu¨berlebensrate gekennzeichnet sind. Die Heterogenita¨t der uPTZL und
deren weitgehend unverstandene molekulare Pathogenese erschweren die Etablierung spez-
ifischer therapeutischer Ansa¨tze. Berthold Streubel et al. [178] war es mo¨glich, innerhalb
der uPTZL das wiederkehrende Translokationsereignis t(5;9)(q33;q22) zu identifizieren,
was zur Expression einer neuen Fusionskinase, ITK-SYK, fu¨hrt. Sowohl ITK als auch
SYK sind gut charakterisierte Tyrosinkinasen und wichtige Bestandteile Antigenrezeptor-
vermittelter Signaltransduktion. Die zellula¨ren Folgen der ITK-SYK Aktivierung hingegen
sind ungekla¨rt.
Ziel der vorliegenden Arbeit war es, den Einfluss von ITK-SYK auf T- bzw. B-Zellen
zu untersuchen und der Frage nachzugehen, ob ein ursa¨chlicher Zusammenhang zwis-
chen der Expression der Fusionkinase und der Entstehung einer malignen T-Zell prolif-
erativen Erkrankung besteht. In vitro Experimente zeigten, dass ITK-SYK konstitutiv
mit T-Zell lipid rafts assoziiert ist und zur aktivierenden Phosphorylierung der T-Zell
Rezeptor (TZR) proximalen Signalmoleku¨le PLCγ1, SLP-76 und LAT fu¨hrt. Zusa¨tzlich
induzierte ITK-SYK die Aktivierung von AKT und der MAPKinasen p38 und ERK1.
Letztendlich zeigten ITK-SYK exprimierende T-Zellen Merkmale akuter Aktivierung,
wie die Expression des Oberfla¨chenmarkers CD69 und die Sekretion des T-Zell stim-
ulierenden Zytokins IL-2. Die Tatsache, dass anti-CD3/CD28 stimulierte T-Zellen a¨hn-
liche Aktivierungsmerkmale aufwiesen wie ITK-SYK exprimierende T-Zellen, fu¨hrte zur
Hypothese, dass ITK-SYK in der Lage ist, Aspekte eines TZR/kostimulatorischen Sig-
nals zu immitieren. Zur Untersuchung des onkogenen Potentials der Fusionskinase wurden
konditionale transgene Mauslinien generiert, die mittels des Cre/loxP Rekombinasesys-
tems eine Zelltyp-spezifische Expression von ITK-SYK ermo¨glichen. Tatsa¨chlich entwick-
elten Ma¨use mit T-Zell spezifischer ITK-SYK Expression Krankheitsymptome wie Ap-
athie, gekru¨mmte Haltung mit einer abdominalen Umfangsvergro¨ßerung, die anatomisch
durch eine ausgepra¨gte Splenomegalie zu erkla¨ren war. Die Tiere starben in einem mit-
tleren Alter von 21 Wochen. Pheriphere ITK-SYK exprimierende T-Zellen expandierten
in der Maus und zeigten einen aktivierten Pha¨notyp, der sich durch eine Zellgro¨ßen-
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zunahme sowie der Expression des Aktivierungsmarkers CD44 und des Verlustes von
CD62L, auszeichnete. Histologische Analysen zeigten ferner, dass die T-Zellen positiv
fu¨r den Proliferationsmarker Ki-67 waren. Ihr klonales, infiltratives Wachstum in lym-
phoide und nicht-lymphoide Organe sowie ihre Transplantierbarkeit charakterisierte die
lymphoproliferative Erkrankung als malignes PTZL. Interessanterweise zeigte eine B-Zell
spezifische Expression der Fusionkinase keine Auswirkung auf B-Zell Entwicklung oder
B-Zell Aktivierung. Da ITK-SYK spezifisch in lipid rafts von T-Zellen, jedoch nicht von
B-Zellen detektierbar war, ist es mo¨glich, dass der pha¨notypische Unterschied auf einer
fehlenden Membranrekrutierung von ITK-SYK basiert. Diese in vivo Beobachtung wa¨re
in Einklang mit den in vitro durchgefu¨hrten Mutationsanalysen, die gezeigt haben, dass
sowohl die enzymatische Aktivita¨t als auch die korrekte Membranpositionierung no¨tig ist,
um das aktivierende Potential von ITK-SYK zu vermitteln.
Zusammenfassend la¨sst sich sagen, dass in dieser Arbeit Mausmodelle fu¨r Zelltyp-
spezische Expression der Fusionskinase ITK-SYK generiert wurden und somit erstmals
der ursa¨chliche Zusammenhang zwischen in vivo Expression der Fusionskinase und der
Entstehung eines PTZLs gezeigt werden konnte. Anhand dieser Mausmodelle sollte es
mo¨glich sein, die Bedeutung individueller Signalmoleku¨le bzw. Signalwege in der ITK-SYK
vermittelten Pathogenese von PTZL zu untersuchen. Basierend auf diesen Erkenntnissen
ko¨nnten neue therapeutische Ansa¨tze angedacht und pra¨klinisch im Mausmodel unter-
sucht werden.
Abstract
Peripheral T cell lymphomas (PTCL), not otherwise specified (NOS), belong to the cate-
gory of the most aggressive non-Hodgkin Lymphomas (NHL). They are associated with a
high mortality rate, minimal effectiveness of conventional chemotherapy, and only 10-30%
longterm survival. The molecular pathogenesis of this heterogenous group of lymphomas is
not well understood, and pre-clinical animal models for the disease are lacking. Recently,
the chromosomal translocation t(5;9)(q33;q22) was identified as a recurrent and specific
genomic alteration in a subgroup of PTCL-NOS. This translocation fuses the spleen ty-
rosine kinase (SYK) gene to the interleukin-2 (IL-2)-inducible T cell kinase (ITK) gene,
leading to the expression of the fusion tyrosine kinase ITK-SYK. Both, ITK and SYK are
required for normal antigen-induced lymphocyte activation, however, the molecular and
cellular consequences of ITK-SYK expression in lymphocytes are unknown.
By combining in vitro analysis with the generation of conditional mouse models
expressing the fusion kinase ITK-SYK in a cell-type specific manner, it is shown that
ITK-SYK associates constitutively with lipid rafts in T cells and triggers antigen inde-
pendent phosphorylation of T cell receptor (TCR) proximal proteins such as SLP-76, LAT,
and PLCγ1. These events lead to constitutive activation of downstream AKT, ERK and
p38 MAP kinase pathways and induce acute cellular outcomes that correspond to regular
TCR ligation, including upregulation of CD69 and production of Interleukin-2 in vitro,
as well as deletion of thymocytes and activation of peripheral T cells in vivo. Ultimately,
conditional expression of ITK-SYK in mice induces malignant PTCLs with 100% pene-
trance carrying features reminiscent of the human disease. The work at hand provides data
demonstrating that ITK-SYK constitutively engages antigen receptor signaling pathways
in T cells, eventually culminating in the development of malignant PTCLs. Therefore in
vivo evidence is provided that constitutively enforced antigen receptor signaling can, in
principle, act as a powerful oncogenic driver in lymphoma pathogenesis. Moreover, a clin-
ically relevant model of PTCL was generated. It can serve as a valuable tool in identifying
and verifying compounds for treatment strategies against PTCL.
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Chapter 1
Introduction
1.1 Adaptive Immunity
1.1.1 Features
Triggering cellular responses to pathogenic intruders or nonself structures arising from
within the organism itself requires crosstalk between immune cells and functional signaling
within the involved cells. The immune system can be roughly divided into two branches:
the innate and the adaptive immune response. Distinct in their timing and ways of
attacking, however, the adaptive and the innate immune cells are interdependent and
work together in their joint endeavor for protection [90].
The major players of the adaptive immune response are T cells and B cells. One
common feature of both lymphocytes is their surface expression of a clonotypic antigen
receptor. These multiprotein complexes termed the T cell receptor (TCR) and the B cell
receptor (BCR) are specialized in antigen recognition and are the starting point from
where signal transduction is initiated. A network of transmembrane and intracellularly
located proteins and other molecules are responsible for relaying the signal from the anti-
gen receptor (AgR) towards the nucleus, inducing cellular outcomes as distinct as cell
survival, proliferation, differentiation or cell death. In the case of an activating scenario,
naive mature lymphocytes expand clonally upon antigen encounter and develop into effec-
tor cells, taking part in clearing the pathological situation [90]. Yet, adaptive immune cells
can become subject to transforming processes, potentially leading up to the development
of lymphoid leukemia or lymphoma [98, 162, 5].
Since both developing and activated T cells and B cells are the subject of investiga-
tion as to whether de novo expression of the previously described fusion kinase ITK-SYK
[178] mediates lymphomagenesis, fundamentals on both cell types will first be given.
Additionally, the main concepts and players in the signaling pathways emerging down-
stream of the TCR and the BCR complex will be outlined. On this basis, the results in
1
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the work at hand will be discussed and interpreted.
1.1.2 T Cell and B Cell Development
Both T cells and B cells develop from common lymphoid progenitors generated in the
bone marrow. While B cell development is continued in the same environment, early T
cell progenitors colonize the thymus to complete their development [90].
T cell development is characterized by a chemokine-driven migration of T cell progen-
itors throughout anatomically distinct thymic regions [180]. During this process, matura-
tion and selection of thymocytes occurs, eventually leading to the release of naive mature
T cells to colonize secondary lymphatic organs [127]. The majority of T cells present in
secondary lymphoid organs are αβ T cells, referring to the expression of a TCRα and
TCRβ chain. During development, αβ T cells have to master several selection steps.
First, successful TCRβ gene rearrangement with subsequent preTCR complex formation
has to occur at the stage of double negative (DN) thymocytes, as are defined by their
lack of CD4 and CD8 coreceptor expression. Having passed this so called beta selection,
DN thymocytes initiate CD4 and CD8 gene expression and mature to the double positive
(DP) state. After successful rearrangement of the TCRα gene locus, surface expression
of both the TCRα and the TCRβ chain takes place. Together with the already expressed
CD3 molecules, a full TCR complex is formed and transferred onto the cell surface [31].
According to an avidity model, DP thymocytes which successfully, yet weakly, recognize
self peptides bound to major histocompatibility complexes (MHCs), are positively se-
lected, thus rescued from apoptosis and mature to the single positive (SP) state, either
expressing the CD4 or the CD8 coreceptor [31]. In the case of a high avidity interaction
between the TCR and MHC/self peptide complexes, however, DP thymocytes undergo
negative selection and die [31]. Rescued naive mature SP T cells leave the thymus and
colonize secondary lymphatic tissues.
In accordance to T cells, maturing B cells are screened for successful immunoglobulin
(Ig) heavy and light chain expression, as well as for their potential risk of recognizing
self antigens [103]. In brief, B cell progenitors evolve to a pro B cell state by rearranging
their heavy chain Ig locus. Upon successful signaling from a pre-BCR complex, pro B cells
mature to the pre B cell state. At this stage, the light chain Ig locus is rearranged which
leads to the expression of a full BCR complex on the cell surface, obtaining the status quo
of an immature B cell [103]. The BCR complex now consists of a surface IgM molecule
associated with the signaling relevant Igα and Igβ molecules. By interacting with stromal
cells, immature B cells are exposed to self antigens. B cells expressing AgRs which do
not show self peptide recognition receive a survival signal and mature. Recognition of
self antigen, however, leads either to its death by apoptosis, a state of unresponsiveness
or the cell is offered one more round of Ig light chain rearrangement in the hopes of
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passing negative selection [103]. Hence, successfully selected immature B cells enter the
periphery to evolve to mature IgM, IgD expressing recirculating B cells. Within the spleen,
the majority of B cells develop into Follicular (FO) B cells. These cells are recirculating
compared to a minority of B cells residing in a specific area within the spleen, thus referred
to as marginal zone B cells [103].
For both lymphocytes, signaling from the AgR, either in its preliminary or its com-
plete state, seems to direct T cell [126] and B cell fates [65]. Investigations of several
knockout or mutant mouse strains have shown that the lack of AgR-associated immunore-
ceptor tyrosine-based activation motif (ITAM)-carrying CD3 or Ig chains as well as the
lack of molecules involved in AgR signaling lead to impaired T cell or B cell development
at specific stages. Amongst the signaling components are the receptor proximal Rous
sarcoma oncogene (SRC) kinase family and the spleen tyrosine kinase (SYK) family as
well as a set of scaffold proteins implementing signal relay [126, 65]. The importance of
individual molecules for correct TCR or BCR signaling in mature cells will be described
in Subsection 1.2.1 and Subsection 1.2.2, respectively.
1.1.3 T Cell and B Cell Activation
Upon successful development, lymphocytes recirculate through secondary lymphoid
organs in a mature but still naive state and await proper antigen stimulation, inducing
proliferation and eventual effector cell differentiation. B cells become antibody producing
plasma cells, T cells become T helper cells, cytotoxic T cells, or regulatory T cells [90].
Additionally, activation may also lead to the development of memory T cells and B cells,
which enable a faster immune response upon secondary antigen encounter [90].
Focusing on cytotoxic and helper T cells, the initial signal for activation is provided
by TCR-mediated recognition of MHC-coupled antigen on antigen presenting cells (APCs)
such as macrophages, dendritic cells or B cells [90]. This interaction is accompanied by
binding of the T cell coreceptor CD8 or CD4 to its respective MHC class I or class II
molecule [90]. However, it is not until costimulation is shared between the two communi-
cating cells that full T cell activation is reached [90]. The best investigated costimulatory
molecule expressed on T cells is the CD28 receptor, which interacts with the B7 family
members CD80 and CD86. Both molecules are upregulated on activated APCs [70]. With-
out costimulation, cells either die or enter a state of unresponsiveness known as anergy
[90].
Proliferating T cells undergo several changes affecting, e.g., their cell size, surface
marker expression and cytokine secretion. Upon antigen encounter and costimulation,
T cells have been shown to lose the naive homing receptor L-selectin (CD62L) [143],
whereas other proteins involved in cell adhesion are upregulated, e.g., the hyaluronate
receptor CD44 [27]. Upregulation of the C-type lectin CD69 has been linked to a state of
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early cellular activation [73], as has the secretion of the auto-/paracrine acting cytokine
Interleukin-2 (IL-2) [172]. Coherently, upregulation of the IL-2 receptor α chain (CD25)
occurs [30], enabling surface expression of a high affinity trimeric IL-2 receptor complex
[112]. It has been shown that CD28 receptor signaling enhances IL-2 production, thereby
promoting cell survival and proliferation [19]. Ambivalent in its outcome, however, IL-2
signaling may also induce apoptosis upon TCR stimulation, which is known as activation
induced cell death (AICD) [111, 47].
Similar to the T cell, B cell activation necessitates antigen recognition by the
BCR. Antigen mediated receptor crosslinking and interaction of the coreceptor complex
(CD19/21/81) with complement proteins (C3d/C3dg) induces antigen uptake, processing
and presentation of MHC bound peptides on the B cells surface [90]. For the majority of B
cells, the necessary costimulatory input is provided through interaction with T helper cells
of the same antigenic specification. T cell recognition of the MHC/antigen complex along
with CD40L/CD40 interaction and cytokine production mediates B cell proliferation und
further differentiation [90]. Besides cellular blasting, a classical feature of activated B
cells is the upregulation of CD80 and CD86 molecules [70], thus in return providing the
precedingly mentioned costimulatory signal needed for T cell activation.
1.2 Antigen Receptor Signaling
1.2.1 T Cell Receptor Signaling
Having described the extracellular events leading up to T cell and B cell activation,
the focus will now be set on the intracellular events mediating signal transduction. Albeit
distinct in their antigen recognition and cellular function, T cells and B cells share common
features of signal transduction [90]. Within this Subsection, principles of TCR signaling
will be outlined. Subsection 1.2.2 will then complement the picture for AgR signaling in
B cells.
In its most reduced version, TCR signaling can be divided into three different phases:
signal initiation, signal amplification and signal diversification [106]. Although various
studies have elucidated the role of individual molecules in TCR signal transduction, the
question on how the interaction between the TCR/coreceptor and the MHC/antigen com-
plex conveys signal initiation has not been clarified yet [117]. The concepts of receptor
clustering upon MHC/peptide interactions as well as conformational changes of the
TCR-associated CD3 chains are likely to play a role in signal initiation [171]. These
events are thought to increase both proximity and accessibility of the TCR complex to in-
tracellular signal transducers [171]. Another principle for promoting molecular proximity
is compartmentalization. Signaling components such as kinases or scaffold proteins have
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been shown to preferentially reside in lipid rafts. These are enriched membrane areas with
a high density of sphingolipids in its exoplasmatic leaflet and phospholipids with saturated
fatty acids in its inner leaflet [168]. These tightly packed membrane areas are recognized
as essential mobile signaling platforms within the membrane bilayer [168]. Besides the
affinity of non receptor signaling components, an increased affinity towards lipid rafts has
also been seen for the TCR complex itself upon ligand interaction [130]. Eventual raft
aggregation accompanies T cell synapse formation, an area of close contact between the
T cell and the APC, where its signal outcome is thought to be determined [51].
Despite the remaining question on how signal initiation is accomplished, it is certain
that TCR ligation results in the activation of the SRC family of protein tyrosine kinases,
such as the lymphocyte specific protein tyrosine kinase (LCK) and the FYN oncogene
related to SRC, FGR, YES (FYN) [117]. As the main initiating kinase, LCK, phosphory-
lates the commonly shared ITAM amino acid sequence utilized in signal initiation [188].
LCK mediated phosphorylation occurs at two distinctly spaced tyrosine residues in the
ITAM core sequence: YxxL/I-X6−8-YxxL/I [147]. Each TCR complex provides ten ITAMs
located in the receptor associated CD3 chains, namely the CD3ǫ/γ, CD3ǫ/δ heterodimers
and the CD3ζ/ζ homodimer (Figure 1.1). The raft associated LCK is fully activated upon
both dephosphorylation by the CD45 phosphatase [153] and trans-autophosphorylation at
the activation loop tyrosine residue within its kinase domain [200]. As soon as kinase prox-
imity to the TCR complex is provided, either through raft clustering [50] or CD4/CD8
coreceptor interaction [185] LCK conveys its enzymatic function. Hence, double phos-
phorylated ITAMs (dp-ITAMs) allow accumulation of the zeta-chain (TCR) associated
protein kinase of 70kDa (ZAP-70) at the CD3 interface. This interaction is achieved
by the tandem SRC homology 2 (SH2) domain binding motif, which is characteristic
for the SYK family of non receptor tyrosine kinases [22]. Upon binding, ZAP-70 leaves
its autoinhibitory state, exposing two linker tyrosine residues for LCK mediated phos-
phorylation, rendering the kinase active [11]. Increased ZAP-70 activity can be further
achieved though trans-autophosphorylation or LCK mediated phosphorylation at a dis-
tinct tyrosine residue within its kinase domain [11]. Continued recruitment and activation
of ZAP-70 completes an important step in signal amplification.
The scaffold proteins linker for activation of T cells (LAT) and the SH2 domain
containing leukocyte protein of 76kDa (SLP-76) are the main targets of ZAP-70 [11]. Once
tyrosine phosphorylated and stabilized by interacting with the growth factor receptor-
bound protein 2 (GRB2)-related adaptor protein 2 (GADS), LAT and SLP-76 become the
heart of an organized conglomerate of interacting proteins [115]. From this point forward,
signal diversification is achieved by engaging three distinct signaling blocks, eventually
affecting cell adhesion, cytoskeleton reorganization and gene expression [2]. Within the
signaling block for gene regulation, three essential transcriptional factor families are known
CHAPTER 1. INTRODUCTION 6
to mediate cell proliferation through initiating IL-2 gene expression: nuclear factor of
activated T cells (NFAT), activator protein 1 (AP-1) and nuclear factor kappa B (NFκB)
[2].
All three families respond to Calcium (Ca2+) dependent signaling pathways for which
phospholipase C gamma 1 (PLCγ1) acts as its gatekeeper. Membrane recruitment of
PLCγ1 occurs upon pleckstrin homology (PH) domain binding to phosphatidylinosi-
tol (3,4,5)-trisphosphate (PIP3) as well as stabilization through interaction with LAT
and SLP-76. Correct positioning of PLCγ1 ensures its proximity to the tyrosine kinase
expressed in hepatocellular carcinoma (TEC) family member, the IL-2-inducible T-cell
kinase (ITK). ITK conveyed tyrosine phosphorylation within the SH2-SH3 linker region
renders a fully active PLCγ1 molecule [8]. Similar to PLCγ1, ITK activation is also de-
pendent on PIP3/PH domain interaction followed by tyrosine phosphorylation by LCK,
trans-autophosphorylation and SLP-76 interaction [8] (Subsection 1.2.3). Subsequently,
activated PLCγ1 enables signal spreading by phosphatidylinositol (4,5)-bisphosphate
(PIP2) hydrolysis, producing the second messengers diacylglycerol (DAG) and inositol
Figure 1.1: The TCR/CD3 and BCR/Ig complex composition. Antigen receptor
(AgR) complexes of T cells and B cells share the immune receptor tyrosine based activation motif (ITAM)
(in yellow), provided by their respective receptor-associated chains. For αβ T cells, the AgR complex
consists of the TCRα/TCRβ chains, associated with the CD3ǫ/γ, CD3ǫ/δ heterodimers chains, and the
CD3ζ/ζ homodimer chain. The AgR on B cells consists of two immunoglobulin (Ig) heavy and light chains
for antigen recognition and the receptor associated Igα/β chains for signal transduction. SRC kinase
family member mediated phosphorylation (red) of two distinctly positioned tyrosine residues establishes
the classical binding motif for the SH2-tandem domain carrying SYK or ZAP-70 kinase, respectively.
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(1,4,5)-trisphosphate (IP3) [149]. Soluble IP3 induces Ca2+ release from the endoplasmatic
reticulum, eventually leading to an additional Ca2+ influx from the extracellular space.
Free cytoplasmic Ca2+ levels are thereby increased and available for interaction, e.g.,
with the Ca2+ receptor calmodulin [141]. Calcineurin interaction with Ca2+/calmodulin
induces dephosphorylation of cytoplasmic NFAT, allowing its nuclear translocation and
binding to the respective IL-2 promoter regions [141].
In contrast to soluble IP3, the membrane localized second messenger DAG func-
tions as a docking site for both the protein kinase C theta (PKCθ) and the ras guanyl
releasing protein 1 (RasGRP). The latter protein acts as guanine nucleotide exchange
factor (GEF) [171]. Upon DAG binding and phosphorylation by PKCθ, RasGRP acti-
vates the small G protein Ras through the delivery of GTP [171]. Subsequently, RasGTP
initiates the classical mitogen-activated protein kinase (MAPK) signaling pathway: the
Raf/MAPK/ERK kinase (MEK)/extracellular signal-regulated kinase (ERK) cascade.
ERK activity, as serine/threonine kinase, results in c-fos gene expression through phospho-
rylation of the transcription factor Elk1 [67]. Upon activation of another MAPK cascade,
namely the MEK kinase (MEKK)/MEK/c-Jun amino-terminal kinases (JNK) module,
c-Jun becomes phosphorylated and through dimerization with c-fos generates the tran-
scription factor AP-1 [167]. Therefore, activation of the MAPK signaling cascades in-
tegrates AP-1 next to NFAT in a cooperative fashion, as essential transcription factor
family for IL-2 gene expression. Additionally, T cell activation results in the activation
of the third group of MAPKs, the p38 members [204]. Besides the described upstream
mediators such as the GEF, VAV1 and the small GTPase proteins cdc42 and Rac, T cells
have acquired a distinct way of p38 activation through ZAP-70 mediated phosphorylation
in a MEK independent pathway [158].
Besides its more recently described role in JNK activation [16], PKCθ leads to the ac-
tivation of the third important transcription factor family for IL-2 gene expression: NFκB
[190]. Within the classical NFκB signaling cascade, PKCθ mediates phosphorylation of the
CARD-containing protein 11 (CARMA1) at distinct linker serine residues, hypothesized
to release CARMA1 from an autoinhibitory to an open conformational state [173, 123].
Subsequent multiprotein complex formation of CARMA1, B cell lymphoma/leukemia
10 (BCL10) and the mucosa associated lymphoid tissue lymphoma translocation gene
1 (MALT1) leads to the activation of the Inhibitor of kappa B Kinase (IKK) α/β/γ
trimeric complex. Activation occurs, on the one hand, by TNF receptor-associated factor
6 (TRAF6) complex mediated lysine (K)63-linked polyubiquitinylation of the regulatory
IKKγ subunit, and, on the other hand, by TGF-beta activated kinase 1 (TAK1) mediated
phosphorylation of the catalytic IKKβ subunit [194]. IKKβ in turn phosphorylates the
NFκB bound IκBα inhibitor, marking it for K48-linked ubiquitinylation and 26S protea-
somal degradation. Thus, heterodimeric NFκB (RelA:p50) is free to translocate into the
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nucleus and promote IL-2 gene expression [190].
Having outlined major signaling steps leading up to IL-2 gene expression, one impor-
tant aspect has to be added. As mentioned in Subsection 1.1.3, complete T cell activation
depends on the integration of the costimulatory signal [90]. CD28 is a key costimulatoy
receptor expressed on T cells [171]. Molecules such as PLCγ1, ITK, pyruvate dehydroge-
nase kinase, isozyme 1 (PDK1) and its substrate v-akt murine thymoma viral oncogene
homolog (AKT) depend on accessible PIP3 for PH domain mediated membrane recruit-
ment and subsequent protein activation. After CD28 interaction with CD80 or CD86
molecules expressed on activated APCs, the cytoplasmic tail of CD28 becomes tyrosine
phosphorylated by LCK. This step creates a platform for phosphatidylinositol 3-kinase
(PI3K) recruitment, which upon activation phosphorylates PIP2 and generates the dock-
ing motif PIP3 [171]. Thus, the CD28/PI3K module provides an important aspect in
signal amplification for full T cell activation. Downregulation of signaling events occurs
via lipid phosphatase or protein tyrosine phosphatase activity, in combination with protein
degradation [90].
Figure 1.2 depicts key signaling steps and molecules involved in the signal transduc-
tion downstream of the TCR/CD3 complex, the coreceptors CD4/8, and the costimula-
tory molecule CD28 upon antigen/MHC encounter in respect to initiating T cell prolif-
eration. Eventually, signals from various cascades are integrated through the binding of
the transcriptional factor family members NFκB, NFAT, and AP-1 to the IL-2 promoter
region, mediating T cell proliferation [84].
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Figure 1.2: Key TCR signaling events. Depicted is a simplified scheme on TCR down-
stream signaling events leading to IL-2 gene expression. Receptor clustering is initiated by both TCRα,
β chain recognition of processed antigen and coreceptor CD4 or CD8 binding to it respective MHC
molecule. Hence, the SRC kinase LCK is activated by CD45 mediated dephosphorylation and trans-
autophosphorylation. Upon phosphorylation of ITAM based tyrosine residues within the CD3 molecules,
ZAP-70 is recruited. ZAP-70 mediates phosphorylation of the scaffold proteins LAT and SLP-76, which
enables signalosome assembly by recruitment of other proteins, such as GADS, PLCγ1 and ITK, into its
core structure. Signal diversification is achieved by ITK dependent PLCγ1 activation and generation of
the second messengers DAG and IP3. DAGmediated recruitment of PKCθ and RasGRP engage the NFκB
and MAPK signaling pathways, while IP3 induces Ca2+ dependent activation of Calcineurin. All three
cascades come together by nuclear translocation of the key transcriptional factor families NFκB, AP-1
and NFAT, promoting IL-2 expression. Signal relayed by the costimulatory CD28 molecule is integrated
by recruitment and activation of PI3K, generating PIP3 for PH domain mediated membrane recruitment,
e.g. of PLCγ1 and ITK. Further information on phosphorylation events or molecular interactions is given
in Subsection 1.2.1.
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1.2.2 B Cell Receptor Signaling
Similar to the model proposed for TCR engagement, BCR signal initiation is thought to
be achieved by antigen mediated BCR crosslinking, movement into lipid rafts and con-
formational changes of the BCR complex [53]. These steps again reflect the key issues of
accessibility and proximity between the AgR and the involved signaling components as
precedingly described for T cells (Subsection 1.2.1). Thus, ITAM carrying Igα, β chains
(Figure 1.1) are subject to SRC or SYK kinase mediated phosphorylation, which re-
sults in an increased recruitment of SYK via its tandem SH2 domain [61]. The main
SRC kinases involved in BCR signaling are the v-yes-1 Yamaguchi sarcoma viral related
oncogene homolog (LYN), the FYN oncogene related to SRC, FGR, YES (FYN), and
the B lymphoid tyrosine kinase (BLK) [102]. Through dp-ITAM binding, SYK enters
a conformationally susceptible state for further activation [9]. Upon either autophos-
phorylation or SRC kinase phosphorylation, SYK becomes fully activated (Subsection
1.2.4) and phosphorylates its main target: the B cell linker (BLNK) protein [60, 197].
Phosphorylated BLNK, which is homologous to SLP-76 in T cells, acts as a backbone
for recruiting key signaling components, such as PLCγ2 and the Bruton agammaglob-
ulinemia tyrosine kinase (BTK). In addition to PIP3 binding, BTK and PLCγ2 are
thereby correctly positioned at the membrane for phosphorylation and further activa-
tion [102]. Interestingly, BLNK also promotes sustained SYK activity by directly in-
teracting with a C-terminally located tyrosine residue [99]. In B cells, PI3K activity is
promoted upon CD19/CD21/CD81 coreceptor complex interaction with the complement
factors C3d/C3dg. Recruitment and activation of LYN, the GEF VAV1, Rac and the
PI3K itself establishes PI3K activity and ensures PIP3 generation [102]. As described for
TCR signaling (Subsection 1.2.1), PLCγ2 hydrolyses PIP2 into the second messengers
DAG and IP3. IP3 induces Ca2+ dependent signaling pathways. DAG availability leads
to PKCβ and RasGRP3 activity, resulting in the initiation of the NFκB and MAPK sig-
naling pathways, respectively. In concert with calcineurin activity, the nuclear release of
the NFκB, NFAT and AP-1 transcription factor family members is engaged, regulating
B cell responses [102]. As is the case in T cells, the main negative feedback mechanism
include dephosphorylation of tyrosine residue and lipid structures, and ubiquitin related
protesomal degradation [90].
1.2.3 The IL-2 Inducible T Cell Kinase
Since studies conducted within this work at hand focus on the fusion kinase ITK-SYK
[178], an overview of the individual kinases affected by the translocation event
t(5;9)(q33;q22) shall be given. ITK belongs to the TEC family of non receptor tyro-
sine kinases [145]. Next to TEC and the resting lymphocyte kinase (RLK), ITK is the
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most abundantly expressed family member in T cells [145]. Other family members include
the bone-marrow tyrosine kinase gene on chromosome X (BMX) protein and BTK, latter
being the main TEC kinase expressed in B cells [129]. While ITK exerts its function as
TEC kinase in TCR signaling (Subsection 1.2.1), BTK does so correspondingly in BCR
signaling events (Subsection 1.2.2). Knockout in vivo analysis in combination with in
vitro studies depicted modulatory roles for ITK in a plethora of T cell processes such as T
cell development, T cell activation, T cell cytoskeleton rearrangement and T cell effector
function [8].
Structurally, ITK consists of an N-terminally located PH domain, a TEC homology
domain (TH), as well as an SH3 and SH2 domain followed by the C-terminally located
tyrosine kinase domain [87] (Figure 1.3). The TH domain itself is composed of a Zn2+-ion
binding area, referred to as the BTK homology domain, and a proline rich region (PRR)
sequence motif [87]. Together, these domains constitute a platform for ITK regulation
suggested to occur via intra- and intermolecular protein interaction, phosphorylation and
peptide bond isomerization. The following steps have been postulated to be important for
full ITK activation [145, 87]: PH domain mediated membrane recruitment through PIP3
Figure 1.3: Schematic view of the ITK protein domain structure. ITK is character-
ized by its N-terminally located Pleckstrin homology (PH) domain, followed by a TEC homology (TH)
domain, a SRC homology (SH)2 and SH3 domain, and an C-terminally located tyrosine kinase domain
(Kinase). The following steps are implied in stabilizing ITK in its active state: PH domain mediated
membrane recruitment via PIP3 binding, cis to trans isomerization of an SH2 domain located proline
residue, as well as phosphorylation of the SH3 and kinase domain. On the other hand, reduced PIP3
availability and intermolecular SH3/SH2 domain interactions are discussed to promote ITK inactivation.
The inactive state might be further supported by PH domain mediated oligomerization as indicated by
the double-headed arrow.
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binding [12], LCK mediated phosphorylation at tyrosine residue Tyr511 within the activa-
tion loop of the catalytic center [75], and isomerization from a cis to trans configuration of
the proline residue Pro287 within the SH2 domain [120]. Together, these steps can be inter-
preted to result in a conformational change of ITK by loosening intermolecular SH3/SH2
and intramolecular SH3/PRR interactions, increasing its affinity for the activated form of
the SLP-76 (pTyr145)/LAT signalosome [8]. SH2 and SH3 domain mediated interaction
with SLP-76 has been shown to support ITK membrane recruitment, and to stabilize
ITK activity [18, 86]. Consequently, active ITK is correctly positioned at the membrane
to phosphorylate its main target PLCγ1 at tyrosine residue Tyr783, contributing to its
activation [114, 78].
Besides target phosphorylation, ITK phosphorylates itself at tyrosine residue Tyr180
within the SH3 domain [88]. This autophosphorylation is suggested to modulate SH3 do-
main/protein interactions, and to promote ITK self-association through intermolecular
SH3/SH2 interaction [87]. ITK oligomerization is thought to be the initial step in sub-
sequent downregulation of ITK catalytic activity [87] and might also be supported by
intermolecular PH domain interaction [80]. Next to the structural changes, ITK kinase
activity is reduced through phosphoinositide phosphatases, such as the phosphatase and
tensin homologue (PTEN), which simply limits PIP3 availability through dephosphoryla-
tion [166]. Protein tyrosine phosphatase activity by dephosphorylation of activation loop
tyrosine residues [87] or dephosphorylating of SLP-76, as ITK interaction partner, are also
discussed to contribute to ITK downregulation [8]. Next to its function as kinase, ITK
has also been postulated to function as scaffold protein in recruiting the GEF VAV1 to
SLP-76. Eventually, this step induces the Rac/Rho/Cdc42 MAPK signaling cascade which
regulates T cell cytoskeleton rearrangement [49]. Despite its importance as TCR signal-
ing molecule, however, to date few mutations affecting the ITK locus have been identified
to be linked to the development of human lymphoproliferative diseases [81]. In terms of
chromosomal aberrations, the ITK gene locus is invovled in translocation t(5;9)(q33;q22)
[178]. Next to ITK, the translocation affects the SYK gene locus, resulting in the expres-
sion of the fusion kinase ITK-SYK (Section 1.4). This translocation was identified in a
subgroup of patients diagnosed with peripheral T cell lymphoma, not otherwise specified
(PTCL-NOS) (Section 1.3).
1.2.4 The Spleen Tyrosine Kinase
The SYK non receptor tyrosine kinase family consists of its original member SYK and
the currently only other member described in mammals, ZAP-70 [177]. SYK is expressed
in various cell types but most abundantly found in hematopoietic cells [128]. Analysis of
SYK deficient mice depicted a profound role for SYK in pro to pre B cell and immature to
mature B cell development, hinting at a key role in pre BCR and BCR signaling [186, 33].
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Originally, the importance of SYK was restricted to signaling from classical ITAM coupled
AgRs or ITAM containing Fc receptors [128]. However, SYK has been shown also to signal
from non classical, so called HemITAM carrying receptors, e.g., C-type lectins, or even
from non ITAM carrying receptors, such as integrins [128]. Therefore, as diverse as its
involvement in signaling cascades, SYK contributes to a multitude of cellular responses,
for instance, cell development, proliferation, differentiation, phagocytosis, cytotoxicity,
and cell adhesion [128].
The function of SYK in adaptive immune cells is best understood for relaying BCR
activation to downstream events through binding to dp-ITAMs, which are located in the
Igα and Igβ chains (Subsection 1.2.2). Structurally, this binding is conveyed through two
N-terminally located SH2 domains, which are connected by an amino acid stretch termed
Interdomain A. Interdomain B, on the other hand, connects the tandem SH2 domain mod-
ule with the C-terminally located tyrosine kinase domain [9] (Figure 1.4). In resting lym-
phocytes, the majority of SYK molecules are located in the cytoplasm in an enzymatically
dormant state. Insights into the full-length crystalline structure of ZAP-70 [46] in combi-
nation with single particle electron microscopy of full length SYK [9] have proposed that
SYK is kept in an autoinhibitory state by intramolecular interactions of the interdomains
A and B with its kinase domain (Figure 1.4) [46, 9]. Upon dp-ITAM binding, however, the
autoinhibitory confirmation is disturbed, promoting SYK to enter a catalytically active
Figure 1.4: Schematic view of the SYK protein domain structure. SYK is
characterized by its N-terminally located tandem SH2 domains (SH2) and its C-terminally located tyro-
sine kinase domain (Kinase). Intramolecular interaction of both, the SH2-SH2 amino acid linker A region
(A) and the SH2-kinase linker B region (B) stabilize SYK in a conformationally inactive state. Upon
interaction with double phosphorylated (red) ITAM based tyrosine (Y) residues, SYK enters a confor-
mationally open state. Tyrosine phosphorylation (arrows) within the kinase domain, the linker regions A
and B as well as the C-terminus offer a platform for positive and negative regulatory actions.
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form [9]. Autophosphorylation or SRC kinase mediated phosphorylation of the activation
loop tyrosine residues (Tyr525/526) establish full kinase activity [203]. Sustained SYK
activity is hence thought to be promoted in an ITAM independent fashion [184] through
autophosphorylation of linker tyrosine residues [63]. Phosphorylation of a C-terminally lo-
cated tyrosine residue has also been discussed [99]. These phosphorylation sites constitute
a platform for recruiting binding partners such as BLNK [99], VAV1 [45], PI3K(p85) [131],
PLCγ2 [71], or PLCγ1 [107]. Within this model, both protein binding and phosphoryla-
tion contribute to stabilize SYK in its open, catalytically active form. Notably, in contrast
to ZAP-70, SYK is neither dependent on SRC kinases to convey tyrosine phosphorylation
of ITAMs [155] nor to phosphorylate its kinase domain [63]. This gives SYK the choice of
establishing its own positive feedback loop for sustained signaling in a SRC kinase inde-
pendent matter. Negative regulation of SYK has been described to occur by promoting
re-entrance into the autoinhibitory conformation through dephosphorylation of linker and
activation loop tyrosine residues [102]. One possible tyrosine phosphatase which takes over
SYK dephosphorylation is SHP-1 [148]. Another mechansim for SYK negative regulation
occurs through the Casitas B-lineage lymphoma (CBL) ubiquitin ligase [118]. Upon BCR
stimulation, CBL binds to phosphorylated Tyr323 in the linker B region of SYK. Hence,
SYK ubiquitinylation is induced, marking the kinase for proteasomal degradation [118].
Further, phosphorylation of linker A Tyr130 induces SYK detachment from BCR ITAMs,
promoting SYK downregulation [91, 207].
Besides its role in regular cell signaling, SYK has been implicated in the pathogenesis
of both hematopoietic and non hematopoietic diseases [128]. Aberrant SYK activity in
lymphocytes has been mainly linked to cancer of B cells either in a developmental stage,
such as pre B cell acute lymphoblastic leukemia or in a mature stage, such as B cell
lineage chronic lymphocytic leukemia or B cell lymphoma [128]. Its role in disease devel-
opment most likely derives from the fact, that SYK as signaling molecule downstream of
the preBCR or BCR is essential for conveying cell proliferation, differentiation as well as
anti-apoptotic signals [128]. When carried out in a deregulated fashion, both actions can
contribute to cell transformation. The role of SYK in B cell malignancies has been sub-
stantiated by successes in clinical trials applying the SYK small molecule inhibitor R788
[58]. Notably, data have been emerging, which hint at an additional role for SYK in the
development of T cell lymphoma. Streubel et al. [178] identified the translocational event
t(5;9)(q33;q22) for a subgroup of patients diagnosed with PTCL-NOS. The translocation
results in the expression of the fusion kinase ITK-SYK. Additionally, Feldman et al. [55]
presented data which demonstrated SYK overexpression even in translocation negative
cases of PTCL. These observations thus raised the hypothesis that SYK deregulation is
a common mechanism involved in the process of lymphoma development, not only in
B cells but also in T cells. Interestingly, besides the predominant role of SYK in BCR
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signaling (Subsection 1.2.2), a selective role for SYK in pre-TCR or TCR signaling, such
as in the early DN3 thymocyte stages [135], or in mature CD4+ effector T cells [97], has
been published. Due to the fact that SYK does have the capacity to act not only in a B
cell but also in a T cell environment, aberrant SYK expression might well be associated
with T cell transforming processes. Subsequently, Section 1.3 will focus on a subset of
malignancies derived from mature T cells, namely PTCL-NOS, and will outline both the
fundamentals and the remaining questions on this disease category.
1.3 Peripheral T Cell Lymphoma Not Otherwise
Specified
1.3.1 Definition, Incidence, and Etiology
According to the latest World Health Organization’s classification of tumors of hematopoi-
etic and lymphoid tissues, PTCLs are a highly divers, seldomly occurring and aggressive
group of T cell and natural killer (NK) cell neoplasms [199]. They represent less than
15% of all non-Hodgkin lymphomas (NHL) worldwide [199]. In contrast to T cell lym-
phoblastic leukemias/lymphomas, which originate from T cell precursors or thymocytes,
PTCLs derive from mature post-thymic T cells [57]. They are classified by their primary
site of disease presentation into cutaneous, disseminated, extranodal or nodal cases. The
primary nodal cases can be further divided into the sub-entities of angioimmunoblastic
T cell lymphoma (AITL), anaplastic large-cell lymphoma (ALCL), positive or negative
for the involvement of the anaplastic lymphoma kinase (ALK+/ALK−), and PTCL-NOS
[57]. At 26%, PTCL-NOS account for the largest, yet most undefined and heterogenous
group of PTCLs with a geographically higher prevalence in North America than in Asia or
Europe [193]. Although some morphological subgroups, such as the lymphoepithelioid, the
T-zone, and the follicular variant have been described [44], PTCL-NOS is still regarded as
an exclusion category due to its inhomogeneous histological features and limited molecular
understanding.
Concerning the etiology, to date, no immunological defects, hereditary components
or viral infections have been proven to affect the occurrence of PTCL-NOS. On a cellular
level, the commonly observed histological involvement of inflammatory components in
PTCL-NOS might hint towards a supportive role of chemokines and other inflammatory
factors in the development of PTCL-NOS [163]. Chronic antigen receptor stimulation has
also been discussed in the pathology of PTCLs. However, no experimental proof has been
offered so far which could substantiate either of these aspects as an etiological component
in PTCL-NOS pathology [163].
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1.3.2 Clinical Presentation and Therapeutic Approaches
From a clinical point of view, PTCL-NOS presents itself as a highly aggressive disease
with a poor prognosis, mainly affecting adult males in their fifth to seventh decade of
life [44]. Although PTCL-NOS are described to have a primary nodal presentation, they
are frequently characterized by the involvement of extranodal sites including liver, spleen,
skin, the gastrointestinal tract, peripheral blood as well as the bone marrow. According
to the Ann Arbor staging system, the majority of PTCL-NOS are diagnosed late in the
disease course at stage III-IV, where dissemination of tumorous cells already has occurred
[44].
Currently, conventional treatment options for PTCL-NOS are based on regimens
approved for aggressive B cell lymphomas. These consist of anthracycline-based or
cyclophosphamide/ doxorubicine/ vincristine/ prednisone (CHOP)-based combination
chemotherapy [57]. However, these approaches were little effective with early and high
relapse rates and a 5-year overall survival of 32% after first line treatment [57]. As a
reasonable approach for relapsed and refractory disease autologous or allogeneic stem
cell transplantation (ASCT) as a combinatorial regimen with high dose chemotherapy is
being suggested [146]. The causes involved in the striking therapeutic response differences
between aggressive T cell and B cell lymphomas are currently unsolved and still specu-
lative. However, recent studies provide data showing that especially T cell and NK cell
lymphomas activate drug resistance pathways, for instance, through the expression of the
P-glycoprotein [79]. Another component accounting for bad treatment responses in these
types of lymphomas might stem from an increased expression of BCL-2 and BCL-XL,
both belonging to the class of anti-apoptotic proteins [144]. Thus, due to the unsatisfac-
tory treatment response, alternative strategies are highly warranted and currently being
investigated on their efficacy in PTCL therapy. Classes of new therapeutical agents include
monoclonal antibodies against surface proteins such as CD52, CD4, CD2 or VEGF, fusion
toxins, nucleoside analogons, metabolite analogons such as antifolates, immune modula-
tory agents, proteasome inhibitors and histone deacetylase inhibitors [79]. High hopes
are further being placed in the class of signaling inhibitors, e.g. small molecules directed
against signaling components. Potential targets are the receptor tyrosine kinase platelet-
derived growth factor receptor (PDGFR) alpha, SYK, mammalian target of rapamycin
(mTOR) or anti-apoptotic proteins, such BCL-2 family members [79, 201]. Individual
agents are reviewed in Howman et al. [79]. The Food and Drug Administration (FDA)
approved of Pralatrexate as antifolate for treating relapsed or refractory PTCL in 2009
[134]. Phase II clinical trails investigating the therapeutic effect of the SYK inhibitor
R788 have been completed and await their evaluation also for treating relapse or refrac-
tory PTCL [57]. As for the other agents and small molecules, clinical trials and preclinical
investigations are ongoing, or being initiated either for the single component or for a
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combinatorial regimen approach. Overall, the future of PTCL therapy is seen to rest in
combinatorial approaches of standard regimens and novel agents.
1.3.3 Phenotypic Characterization
Substantial efforts are made to identify phenotypical characteristics in order to provide
the basis for dissecting sub-entities amongst the heterogenous group of PTCL-NOS. By
determining the cellular and molecular variations of individual PTCL-NOS subtypes, the
eventual goal is to understand the clinical implications for diagnosis, therapeutical guide-
lines, and prognosis. Within this Subsection, key phenotypical features of PTCL-NOS in
terms of their morphology, surface expression, as well as recent studies aiming at classi-
fying PTCL-NOS via gene expression profiling, shall be summarized.
Due to their heterogeneity, PTCL-NOS display a high variability also in terms of
their cell morphology. Irregular T cells may differ in size and shape, possibly embedded
in eosinophils, plasma cells, histiocytes, epitheliod cells or in a general reactive cellular
background. Affected mature T cells are derived from the αβ T cell lineage, usually
harboring a clonally arranged T cell receptor with TCRβ surface expression [44]. The
majority of nodal cases show single expression of the T helper cell marker CD4 [154]. Far
less frequently described are CD8 single positive and CD4/CD8 double positive or double
negative scenarios [154]. CD52 is expressed in all neoplastic cells [66], CD30 positivity is
seen in one third of all PTCL-NOS cases [43]. Additionally, a frequent loss is observed
of CD7, seldomly of CD5, CD3, and/or CD2 [44]. Notably, affected T cells show a high
proliferative index as measured by Ki-67 expression [163]. Epstein-Barr Virus (EBV)
positivity, expression of the cytokine receptor CCR4, or the cytotoxic marker CD8 have
also been associated with a dismal effect on patient overall survival [44].
Within the molecular approach to characterize PTCL-NOS subgroups, initial gene
expression study showed that separation was possible according to the expression level
of NFκB pathway genes [122]. Interestingly, low expression was associated with worse
patient survival. A following approach suggested that PTCL-NOS be classified into three
groups, as based on the expression of genes either correlated to tumor promotion (U1),
T cell activation and apoptosis (U2), or mainly genes involved in the Interferon gamma
(IFNγ)/Janus kinase (JAK)/signal transducer and activator of transcription (STAT)
signaling pathway (U3) [13]. Further studies led to the molecularly important insight
that malignant cells resemble activated T cells belonging either to the CD4+ or CD8+
phenotype [139]. Additionally, the authors have demonstrated deregulation of genes in-
volved in tumorigenic processes. These included deregulation of proliferation, apoptosis,
cell cycle, chemoresistance, and of pathways engaged during cell dissemination, such as
matrix remodeling and cell adhesion [139]. A recent study with increased sample num-
bers of PTCL-NOS cases identified a subgroup of PTCL-NOS with an expression pattern
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reminiscent of a cytotoxic T cell phenotype, which correlated to dismal patient survival
[83]. These results are in line with data generated by immunohistochemical analysis [10],
and reflect the CD8+ classification approach by Piccaluga et al. [139].
Overall, gene expression profiling helped to molecularly characterize PTCL-NOS
cases and opened possibilities of subgroup definition. However, validation by large scale
studies with increased PTCL-NOS cohorts is warranted and the diagnostic impact of the
presented classification strategies still needs further investigation.
1.3.4 Genetic Characterization
Classical cytogenetics such as karyotyping or fluorescence in situ hybridization (FISH)
analysis in accordance with comparative genomic hybridization, and single-nucleotide
polymorphism (SNP) analysis have demonstrated that PTCL-NOS genomes display a
high complexity concerning their genomic alterations [43]. Largely, the oncogenicity of
these variations is not understood [57]. Genomic changes include aneuploidy, gains and
losses of chromosomal material, as well as chromosomal translocations. An overview of
documented aberrations is given by de Leval et al. [43].
To date, three chromosomal translocations have been described among PTCL-NOS
for which both affected gene loci were identified and the recurrence of the translocation was
shown [178, 54, 7]. Streubel et al. [178] described the translocational event t(5;9)(q33;q22),
which was present in 17% (5/30) of analyzed PTCL-NOS cases. The translocation affects
the SYK as well as the ITK gene locus, and results in the generation of a novel fusion
kinase, termed ITK-SYK. Histopathologically, all translocation positive cases were clas-
sified as the follicular variant, potentially identifying t(5;9)(q33;q22) as a PTCL-NOS
subtype specific genetic marker [178]. Notably, Feldman et al. [55] showed overexpression
of activated SYK in translocation negative cases of nodal PTCL. Thus, SYK deregulation
might be a common mechanism involved in PTCL pathology. The second two transloca-
tions described for PTCL-NOS involve the TCRα gene locus (TCRA) [54, 7]. Feldman
et al. [54] described 3% (2/64) of PTCL-NOS cases carrying cytotoxic features with skin
and bone marrow involvement to harbor the translocation t(6;14)(p25;q11.2). Molecular
analysis demonstrated repositioning of the multiple myeloma oncogene-1/interferon reg-
ulatory factor-4 (IRF4) to the TCRA gene locus. This event is hypothesized to lead to
IRF4 deregulation. Similar to (5;9)(q33;q22) positive cases, IRF4 translocation might also
function as characteristic for a new subgroup definition. Lastly, Almire et al. [7] looked
at two translocation t(14;19)(q11;q13) positive PTCL-NOS cases previously described by
Martin-Subero et al. [121] and identified the poliovirus receptor-related 2 (PVRL2) gene to
be translocated to the TCRA gene locus [7]. Both patient samples showed overexpression
of PVRL2 [7]. It still needs to be investigated whether T cell transformation correlates to
the genetic event.
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1.4 Translocation t(5;9)(q33;q22) and the Fusion
Kinase ITK-SYK
As summarized in the previous Subsection 1.3.4, few recurrent translocations have been
described for PTCL entities belonging to the category: not otherwise specified. Streubel
et al. [178] published a reciprocal event to affect the chromosomal regions 5q33 and 9q22,
respectively harboring the ITK and the SYK gene locus. Applying rapid amplification
of cDNA ends (RACE), reverse transcriptase polymerase chain reaction (RT-PCR), and
sequence analysis the authors had shown, that the translocational event results in the
generation of two fusion transcripts of which solely the ITK-SYK transcript was sub-
stantiated to be functional [178]. Sequencing identified the in frame fusion to link the
genomic region holding exon 8-14 of the SYK gene locus onto exon 5 of the ITK gene
locus. In this situation, expression of the newly generated fusion transcript is regulated
by the endogenous ITK promoter. On the protein level the translocation results in the
fusion of the N-terminal region of the ITK protein (amino acid 1-165), containing the PH
and the TEC homology (TH) domain, to the SYK kinase domain (amino acid 371-631).
A residual SYK derived linker B fragment (amino acid 306-370) is preserved during this
process, and connects the major protein domain structures of both kinases [178]. In total
ITK-SYK consists of 495 amino acids with an estimated protein size of 55kDa. Figure 1.5
depicts the translocational consequences on the protein level.
Concurrent to this work at hand in vitro investigations by Rigby et al. [151] and
Hussain et al. [82] provided initial insights on ITK-SYK functionality. Both groups of
authors demonstrated that ITK-SYK has retained its catalytic properties as a kinase
and seemingly conveys its activity in a constitutive manner. First kinase targets such
Figure 1.5: Schematic view of ITK, SYK, and the fusion kinase ITK-SYK.
Translocation t(5;9)(q33;q22) results in the generation of the fusion kinase ITK-SYK, retaining the PH
and TH domain from ITK, fused to the enzymatic SYK kinase domain. A residual SYK derived linker
B amino acid stretch is further preserved. Arrows indicate the translocation breakpoints projected onto
the protein level.
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as SLP-76 and BLNK [82], as well as p42/p44 [151] have been identified. In terms of
ITK-SYK conveying its full kinase activity, in vitro experiments additionally showed PI3K
dependency [82, 151] and the necessity for correct membrane localization via the PH
domain [151]. Ribgy et al. [151] complemented these data with first in vitro studies on
the potential oncogenicity of ITK-SYK. The authors demonstrated contact inhibited cell
growth in ITK-SYK expressing NIH3T3 cells, indicating that ITK-SYK is able to cause
cell transformation [151].
Chapter 2
Research Objective
Chromosomal translocations as a specific form of genomic aberration, have long been
associated with cancer development of the hematopoietic system [156, 42]. Two major
scenarios have been described of how translocation events contribute to cellular transfor-
mation. On the one hand, gene deregulation may occur by placing the coding sequence
of one gene under the control of another gene locus. On the other hand, chromosomal
translocation may result in the generation of a new gene product by fusing the coding
regions of two different gene loci [157]. Belonging to the latter category, Streubel et al.
[178] identified a reciprocal translocation which was recurrent in a subgroup of patients
diagnosed with PTCL-NOS . The translocation event t(5;9)(q33;q22) affects the ITK and
SYK gene locus, and results in the functional expression of a new fusion tyrosine kinase
called ITK-SYK. Currently, little is known about the molecular processes behind PTCL
development, which especially holds true for the subgroup of PTCL-NOS, and adequate
tools for its understanding are lacking.
On the basis of the isolated translocation, the research objective of the work at
hand was to investigate the cellular consequences of ITK-SYK activity, and to clarify
whether de novo expression of ITK-SYK may induce lymphomagenesis. The strategic
approach of conditional gene targeting was employed. Therefore, the human ITK-SYK
cDNA was introduced by homologous recombination into the murine, ubiquitously ex-
pressed ROSA26 locus [174]. The conditional approach was realized by the presence of
a loxP site flanked STOP cassette infront of the ITK-SYK cDNA, preventing transcrip-
tional readthrough in ROSA26loxSTOP lox−ITK−SY K mice. Only upon breading with Cre-
transgenic mice, deletion of the STOP cassette and cell type specific expression of the
fusion kinase ITK-SYK would occur. Due to the translocation’s origin, the primary focus
was set on investigating effects of the fusion kinase on T cell biology. In vivo analysis
were supported by in vitro experiments in retrovirally infected JurkatE T cells. However,
due to the essential role SYK plays in B cell development [186, 33] and signaling [37] the
opportunity of the conditional targeting approach was facilitated in order to study the
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potential effect of ITK-SYK activity on B cell properties.
Thus, the scientific intent was to establish a mouse model which offers insights into
ITK-SYK mediated pathogenesis, and which eventually might be useful for pre-clinical
studies on PTCL treatability.
Chapter 3
Materials
3.1 Reagents
If not stated otherwise, all chemicals were purchased from Sigma-Aldrich. Additional
reagent and kit information is provided in the respective methods section.
3.2 Employed Antibodies
3.2.1 Westernblot Analysis
Identification Company
α-phospho-PLCγ1 (Tyr783; rabbit polyclonal IgG) Cell Signaling
α-phospho-tyrosine (P-Tyr-100; mouse monoclonal IgG) Cell Signaling
α-Emt (2F12, mouse monoclonal IgG) Santa Cruz Biotechnology
α-beta-actin (20-33, rabbit polyclonal IgG) Sigma-Aldrich
α-mouse IgG HRP-linked (horse polyclonal IgG) Cell Signaling
α-rabbit IgG HRP-linked (goat polyclonal IgG) Cell Signaling
3.2.2 Stimulation Experiments
Identification Company
functional grade purified α-mouse CD3e (145-2C11) eBioscience
functional grade purified α-mouse CD28 (37.51) eBioscience
functional grade purified α-human CD3e (145-2C4) BD Pharmingen
functional grade purified α-human CD28 (CD28.2) BD Pharmingen
AffiniPure goat α-mouse IgG crosslinking antibody Jackson Immuno Research
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3.2.3 Flowcytometry: Extracellular Staining Panel
Applied antibodies were conjugated to one of the following fluorochromes: phycoerythrin
(PE), phycoerythrin cyanin 5 (PE-Cy5) or allophycocyanin (APC). Exception, the
α-mouse CD16/32 antibody used for Fc receptor saturation was purified and unconju-
gated.
Identification Company
α-mouse B220 (RA3 6B2) eBioscience
α-mouse CD3 (1452C11) eBioscience
α-mouse CD4 (Gk1.5) eBioscience
α-mouse CD5 (53-7.3) eBioscience
α-mouse CD8 (53-6.7) eBioscience
α-mouse CD11b (M1/70) BD Pharmingen
α-mouse CD16/32 (93), purified eBioscience
α-mouse CD21/35 (7G6) eBioscience
α-mouse CD23 (B3B4) eBioscience
α-mouse CD44 (IM7) eBioscience
α-mouse CD62L (MEK-14) eBioscience
α-human CD69 (FN50) eBioscience
α-mouse CD86 (GL1) eBioscience
α-mouse IgM (II/41) eBioscience
α-mouse IgD (11-26) eBioscience
α-mouse TCRbeta (H57-597) eBioscience
α-mouse TCRVβ2 (B20.6) BD Pharmingen
α-mouse TCRVβ3 (KJ25) BD Pharmingen
α-mouse TCRVβ4 (CTVB4) BD Pharmingen
α-mouse TCRVβ5.1/5.2 (MR9-4) BD Pharmingen
α-mouse TCRVβ6 (RR4-7) BD Pharmingen
α-mouse TCRVβ7 (TR310) BD Pharmingen
α-mouse TCRVβ8.1/8.2 (MR5-2) BD Pharmingen
α-mouse TCRVβ8.3 (CT-8C1) BD Pharmingen
α-mouse TCRVβ10b (CTVB10b) BD Pharmingen
α-mouse TCRVβ11 (CTVB11) BD Pharmingen
α-mouse TCRVβ12b (CTVB12b) BD Pharmingen
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3.2.4 Flowcytometry: Intracellular Staining Panel
Antibodies used in phosflow analysis were either conjugated to phycoerythrin (PE) or
Alexa Fluor R©647 (AF647).
Identification Company
α-human AKT (pS473)(M89-61) BD Pharmingen
α-human ERK1/2 (pT202/pY204)(20A) BD Pharmingen
α-human LAT (pY171)(I58-1169) BD Pharmingen
α-human PLCγ1 (pY783)(27/PL) BD Pharmingen
α-human p38 (pT180/pY182)(36/p38) BD Pharmingen
α-human SLP-76 (pY128)(J141-668.36.58) BD Pharmingen
3.2.5 Immunohistochemistry
Identification Company
α-mouse CD3 (SP7) Lab Vision
α-mouse B220 (RA3 6B2) BD Pharmingen
α-mouse Ki-67 (SP6) Lab Vision
α-mouse cleaved Caspase 3 (ASP 175) Cell Signaling
3.3 Employed Primer
Primer were either synthesized at GATCBiotech or MWGBiotech. Previously unpublished
primer sequences were designed using Gene Construction Kit R© software and Net primer
freeware (http://www.premierbiosoft.com).
3.3.1 ITK-SYK cDNA and Mutant Generation
Identification Sequence 5′-3′
is xhoI fwd CTCGAGAACAACTTTATCCTCCTGGAA
itk rev overlap GGCAGGGGAGGACCTGTTGTCTTCAGGAGTAG
syk fwd overlap GAAGACAACAGGTCCTCCCCTGCCCAAGGGA
is ecoRI rev GAATTCAGGTGCGGGAGCGGTTAGTTC
is xhoI fwd CTCGAGAACAACTTTATCCTCCTGGAA
is ecoRI rev GAATTCAGGTGCGGGAGCGGTTAGTTC
is fwd ascI GGCGCGCCCCACCATGAACAACTTTATCCTCCTGG
is rev ascI GGCGCGCCAGGTGCGGGAGCGGTTAGTTC
is kd fwd GTGAAAACCGTGGCTGTGAGAATACTGAAAAACGAGGCC
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Identification Sequence 5′-3′
is kd rev GGCCTCGTTTTTCAGTATTCTCACAGCCACGGTTTTCAC
is ph fwd CCCTCGAACTTTAAAGTCTGCTTCTTTGTGTTAACC
is ph rev GGTTAACACAAAGAAGCAGACTTTAAAGTTCGAGGG
3.3.2 Southern Probe Amplifikation
Identification Sequence 5′-3′
probe fwd GATCAAAACACTAATGAACTT
probe rev TTAATTAAAACGAATATTTGGAAT
3.3.3 Genotyping
Identification Sequence 5′-3′
geno is fwd GATGGATGGGAAGTGGAGGTG
geno is rev GGACCAAGTTCTGCCATCTC
Cre fwd ACCAGCCAGCTATCAACTCG
Cre rev TTACATTGGTCCAGCCACC
Cre7 TCAGCTACACCAGAGACGG
CD19c AACCATTCAACACCCTTCC
CD19d CCAGACTAGATACAGACCAG
3.3.4 Genescan Analysis
When indicated primer were 5′-labeled with 6-carboxyfluorescein (FAM). Primer
sequences have been previously published for the TCRβ [4, 64] and the TCRγ [89] locus.
Identification Sequence 5′-3′
TCRβ-Vβ1 AAATGAGACGGTGCCCAGTCGTT
TCRβ-Vβ2 TCCTGGGGACAAAGAGGTCAAATC
TCRβ-Vβ3 GAAAAACGATTCTCTGCTGAGTGTCC
TCRβ-Vβ4 AGCTATCAAAAACTTATGGACAATCAG
TCRβ-Vβ5 CAGCAGATTCTCAGTCCAACAGTTT
TCRβ-Vβ6 AAGGCGATCTATCTGAAGGCTATGA
TCRβ-Vβ7 AGCTGATTTATATCTCATACGATGTTG
TCRβ-Vβ8 TATATGTACTGGTATCGGCAGGACA
TCRβ-Vβ9 TTCCAATCCAGTCGGCCTAACAAT
TCRβ-Vβ10 GCGCTTCTCACCTCAGTCTTCAG
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Identification Sequence 5′-3′
TCRβ-Vβ11 TTCTCAGCTCAGATGCCCAATCAG
TCRβ-Vβ12 AGCTGAGATGCTAAATTCATCCTTC
TCRβ-Vβ13 CTGCTGTGAGGCCTAAAGGAACTAA
TCRβ-Vβ14 AGAGTCGGTGGTGCAACTGAACCT
TCRβ-Vβ15 CCCATCAGTCATCCCAACTTATCC
TCRβ-Vβ16 GATTTTAGGACAGCAGATGGAGTTTC
TCRβ-Vβ17 TCGAAATGAAGAAATTATGGAACAAAC
TCRβ-Vβ18 CCGGCCAAACCTAACATTCTCAAC
TCRβ-Vβ19 CTACAAGAAACCGGGAGAAGAACTC
TCRβ-Vβ20 CTGGTATCAACAAAAGCAGAGCAAA
TCRβ-Dβ1 GAGGAGCAGCTTATCTGGTGGTTT
TCRβ-Dβ2 GTAGGCACCTGTGGGGAAGAAACT
TCRβ-Jβ1 (FAM) CACAACCCCTCCAGTCAGAAATG
TCRβ-Jβ2 (FAM) TGAGAGCTGTCTCCTACTATCGATT
TCRγ-Vγ4 AGTGTTCAGAAGCCCGATGCA
TCRγ-Jγ1 (FAM) AGAGGGAATTACTATGAGCT
Chapter 4
Methods
4.1 Work with Nucleic Acids
4.1.1 Determination of Nucleic Acid Concentration
The amount of nucleic acid, as ultraviolet light adsorbing molecule [52], was determined
on a NanoDrop R© ND-100 Spectrometer (Peqlab Biotechnologie). An optical density unit
of 1 measured at 260nm (OD260) equals 40µg/ml of single-stranded (ss) RNA and 50µg/ml
of double-stranded (ds) DNA dissolved in water. The amount of adsorbed light is propor-
tional to the amount of nucleic acid in solution, with ratio readings OD260/OD280 being
used as an estimate for sample purity. Pure RNA and DNA preparations result in ratios
of 1.9–2.1 and 1.8–2.0, respectively. Significant protein or phenol contaminations will lead
to reduced ratios.
4.1.2 Agarose Gelelectrophoresis
Agarose gelelectrophoresis was performed to separate or purify negatively charged nucleic
acid according to its size and conformation by migration through an agarose gel matrix
(1-2% agarose (w/v) (BD Biosciences) in TAE buffer (0.4M Tris base, 1.1% (v/v) acetic
acid, 0.5M EDTA). Migration was achieved by applying an electric field (90-150V)[159].
Ethidium bromide (0.5µg/ml, Eurobio), as DNA-intercalating fluorescent dye [62], was
used for DNA visualization after excitation with ultraviolet light of 320nm wavelenght
on a GelDOC 2000 (Bio-Rad Laboratories). For gel loading, samples were resuspended
in 10× DNA loading dye (50% glycerol (v/v), 0.05% bromophenol blue (w/v) (Roth),
1mM EDTA (pH 8.0)). DNA size was determined by comparing the fragment height to
an appropriate DNA standard (100bp or 1kb DNA ladder, Peqlab). Gelectrophesis supply
was purchased from Bio-Rad Laboratories.
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4.1.3 Polymerase Chain Reaction
The polymerase chain reaction (PCR) is used to amplify specific nucleotide sequences.
It consists of three main phases: DNA double strand denaturation, oligonucleotide
hybridization of one or several forward (fwd) as well as reverse (rev) primers, and
DNA sequence amplification by a thermostabile DNA polymerase. These steps are per-
formed in repeated cycles at varying temperatures for maximal but sequence-specific
product amplification [132]. For this work, PCR had been performed as part of several
applications, such as RT-PCR (Subsection 4.1.4), DNA amplification prior to molecu-
lar cloning approaches (Subsection 4.1.6), site-directed mutagenesis (Subsection 4.3.1),
southern probe generation (Subsection 4.1.7), and mouse genotyping (Subsection 4.5.4).
A variation, the so-called touch-down PCR had been performed for genescan analysis
(Subsection 4.1.5). For this specific PCR approach, initial reaction cycles share high an-
nealing temperatures to maximize sequence-true primer binding for stringent product
generation. As the reaction progresses, the annealing temperature of subsequent reaction
cycles decrements to increase specific product amplification.
If not stated otherwise, the amplification reaction consisted of 0.2mM dNTP each
(Bioline), 0.2µM primer each, 50ng template, 0.04U/µl of IllustraTM Taq DNA Polymerase
(GE Healthcare) in reaction buffer (GE Healthcare). When applying the Physion Hot
Start High Fidelity DNA Polymerase (Finnzymes), the reaction set-up was composed of
0.2mM dNTP each (Bioline), 0.5µM primer each, 10ng of DNA, 0.02U/µl of polymerase in
HF reaction buffer (Finnzymes). Reaction volumes were either 25µl or 50µl. PCR cycling
conditions and primer sequences used for the individual application are stated in the
respective chapters. All reactions were carried out on a PCR thermocycler (Biorad).
4.1.4 Reverse Transcriptase-Polymerase Chain Reaction
The technique of reverse transcriptase (RT)-PCR was firstly applied to enzymatically
generate complementary DNA (cDNA) from RNA by reverse transcription, and sec-
ondly to amplify the cDNA region of interest by PCR. As starting material, total RNA
was isolated from either 1×106 JurkatE T cells or 1×106 SuDHL6 cells by using the
TRIzol R© Reagent (Invitrogen). First strand cDNA synthesis was achieved by applying
the SuperScriptTM II RT system (Invitrogen) according to the manufacturer’s instructions
with a 20µl reaction consisting of 1µg total RNA, 0.5mM dNTPs each, 250ng random
primers, 5mM DTT, and 10U/µl of SuperScriptTM II RT. Random hexamer nucleotides
were chosen as primers, consisting of a mixture of every possible six base-long single
strand combination of nucleotides to ensure primer annealing and complete cDNA syn-
thesis throughout the target RNA. Newly generated cDNA was used as a template for
sequence specific amplification with the Physion Hot Start High Fidelity DNA Polymerase
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(Finnzymes) prior to molecular cloning as described (Subsection 4.1.6).
4.1.5 Genescan Analysis
PCR-based and computer-assisted fragment length analysis (genescan) was performed to
assess TCR locus rearrangments in murine primary T cells as described [93, 191]. This
method allows adequate resolution of similar sized PCR products by applying fluorescently
labeled primers to visualize DNA fragments, and a polymer matrice to separate them
according to their size by capillary gelelectrophoresis. 6-carboxyfluorescein (6-FAMTM)
was chosen as 5-prime (5′)-labeling fluorochrome of the reverse primers, with an emission
at 494nm wavelenght after argon laser excitation. Emitted light is directly proportional
to the amount of nucleic acid present in the reaction volume. The resulting data were
graphically displayed in an electropherogram showing fluorescence intensity in relative
fluorescent units (RFU) as a function of the fragment size.
Genomic DNA was extracted by using the GenEluteTM Mammalian Genomic
DNA Miniprep Kit (Sigma-Aldrich) from total splenic cell suspensions of diseased
ITK-SYKCD4−Cre , ITK-SYKCD19−Cre , and control mice (CD4-Cre and CD19-Cre mice,
respectively). The DNA was assayed for clonal gene rearrangements at the TCRβ and the
TCRγ locus. V-D-J and incomplete D-J rearrangements of the TCRβ locus were analyzed
via five individual PCR reactions with the following primer combinations: Vβ(1-20)-Jβ1,
Vβ(1-20)-Jβ2, Dβ1-Jβ1, Dβ2-Jβ2, and Dβ1-Jβ2. Primer sets consisted of a mixture of
20 family-specific upstream primers located within the Vβ gene segments or consensus
primers immediately located 5′ of the Dβ1/Dβ2 rearrangement and 5′-FAM-labeled con-
sensus primers immediately located 3-prime (3′) of the Jβ1/Jβ2 rearrangement as de-
scribed [64]. The TCRγ locus was analyzed for V-J rearrangements by a single PCR
reaction using a Vγ4 and a 5′-FAM-labeled Jγ1 consensus primer as described [89].
Primer sequences for amplification within the TCRβ and TCRγ locus are listed in
Subsection 3.3.4. The 25µl PCR reaction contained 100ng genomic DNA, 0.05U/µl Am-
plitaq Gold DNA-Polymerase, 2.8mM MgCl2, 0.2mM dNTP each (Bioline) and 0.2µM
primer each in GeneAmp PCR Buffer I. PCR cycling conditions for amplifying incom-
plete D-J rearrangements of the TCRβ locus were 95◦C for 5min, 37 cycles of 94◦C for
1min, 63◦C for 40s, 72◦C for 1min, and an end-elongation step at 72◦C for 5min. The
PCR reaction for the TCRγ locus used the same cycling conditions, with the exception
of a lower annealing temperature (57◦C). For the multiplex-PCR reactions Vβ(1-20)-Jβ1
and Vβ(1-20)-Jβ2 a touchdown-PCR approach was chosen with the following conditions:
95◦C for 5min, 16 cycles of 94◦C for 1min, 72◦C for 40s (reduced by 0.7◦C every cycle),
72◦C for 1min, followed by 30 cycles of 94◦C for 1min, 63◦C for 40s, 72◦C for 5min, and
an end-elongation step at 72◦C for 5min. PCR products were size-separated by capil-
lary POP-7TM polymer electrophoresis and visualized via automated scanning with the
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3700 Genetic Analyzer. Gene ScanTM 500HD ROX was used as internal standard. If not
stated otherwise, all reagents for genescan analysis as well as the 3700 Genetic Analyzer
were purchased from Applied Biosystems. Fragment size distribution was determined us-
ing GeneMapper R© software, also obtained from Applied Biosystems. Genescan analysis
was performed together with Julian Holch (medical student in the lab) in cooperation
with Birgit Geist who supplied technical assistance (Institute of Pathology, Technische
Universita¨t Mu¨nchen).
4.1.6 Molecular Cloning
Molecular cloning was performed for the generation of retroviral expression vectors and
the generation of the pROSA26loxSTOP lox−ITK−SY K targeting vector. Standard molecular
biology techniques were applied [159]. In brief, the cDNA of interest (insert DNA), flanked
by specific restriction endonuclease (RE) recognition sites, was first introduced into the
pCR R©II-TOPO R© vector by applying the TOPO TA Cloning R© Kit (Invitrogen). PCR
products amplified by DNA polymerases with proof reading activity, such as the Physion
Hot Start High Fidelity DNA Polymerase (Finnzymes), were pretreated with 0.05U/µl of
the IllustraTM Taq DNA Polymerase (GE Healthcare), 0.2mM dNTP each (Bioline) in
the supplied reaction buffer (GE Healthcare) at 72◦C for 20min. This reaction generates
a single 3′-adenine overhang required for insert ligation into TOPO TA R© cloning vectors.
One Shot R© Top10 chemically competent E.coli (Invitrogen) were used for all TOPO TA
Cloning R© approaches.
Subsequently, a preparative digest was performed. To this end, 2µg of sequence
verified pCR R©II-TOPO R© vector carrying the insert DNA and 2µg of the respective vec-
tor backbone (pMigR1 or pROSA26 targeting vector) were incubated with 1U/µl of the
intended REs o/n at 37◦C. Fragment size confirmation and DNA purification was achieved
by agarose gelelectrophoresis (Subsection 4.1.2). Recovery of the linearized backbone and
the insert DNA from the gel matrix was realized by using the QIAquick R© Gel Extraction
Kit (Qiagen). Purified vector backbone and insert DNA were then fused in an enzymatic
reaction by the T4 Ligase, applying the Rapid DNA Ligation kit (Invitrogen) accord-
ing to the manufacturer’s instructions. In the presence of ATP, the T4 Ligase catalyzes
the formation of phosphodiester bonds between complementary double-stranded DNAs
with 3′-hydroxyl and 5′-phosphate ends. Molar ratios of 3:1, 5:1 and 10:1 of insert:vector
backbone were used for the ligation reaction set-ups with 0.05U/µl T4 Ligase. Success-
fully ligated plasmids were propagated by transformation of Subcloning EfficiencyTM
DH5alphaTM chemically competent E.coli (Invitrogen) according to the manufacturer’s
protocol.
In the case of a bidirectional cloning strategy, which uses only one RE for plasmid
linearization, dephosphorylation of the vector backbone prior to the ligation step was per-
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formed. This was done by adding 0.025U/µl Calf Intestinal Alkaline Phosphatase (CIAP)
(Invitrogen), followed by an incubation step at 37◦C for 1h, and heat-inactivation at 72◦C
for 10min. CIAP catalyzes the hydrolysis of 5′-phosphate groups from the linearized DNA
hence preventing recircularization of the linearized vector backbone. CIAP was subse-
quently removed by applying the QIAquick PCR Purification Kit (Qiagen) before setting
up the final ligation reaction. Bidirectional cloning has been used for the generation of
the pROSA26loxSTOP lox−ITK−SY K targeting vector.
In all molecular cloning approaches chemically competent bacteria were transformed
by heat shock, and cultivated o/n at 37◦C, 225rpm shaking, according to the manu-
facturer’s instructions. Ampicillin-containing Luria-Bertani medium (1% bacto-tryptone
(w/v) (BD Biosciences), 0.5% bacto-yeast extract (w/v) (BD Biosciences), 1% NaCl
(w/v), 50µg/ml ampicillin (adjusted to pH7.0) (Roth) was used for selective bacterial
propagation. Only bacteria which carry recombinant vectors expressing the ampicillin
resistance gene beta-lactamase will grow under these culture conditions [179].
4.1.7 Southernblot Analysis
Southernblot analysis was performed to screen electroporated E14K embryonic stem cells
(ESCs) for homologous recombination within the ROSA26 locus. First described by Edwin
Southern [175], this method consists of the membrane transfer (blot) of electrophoreti-
cally separated DNA fragments, and the fragment identification (detection) via probe
hybridization.
Therefore, individually expanded ESCs were harvested from a 10cm cell culture plate,
washed in PBS, resuspended in TNE lysis buffer (10mM Tris/HCl (pH7.6), 1mM EDTA
(pH8.0), 100mM NaCl, 0.3mg/ml Proteinase K, 0.7mg/ml Pronase E, 0.7% SDS (w/v)),
and incubated over night (o/n) at 37◦C and 600rpm while shaking. Genomic DNA was
isolated via phenol/chloroform precipitation [159]. DNA purity and concentration were
determined as described (Subsection 4.1.1). 20µg of genomic stem cell DNA was digested
with 1.6U/µl XbaI (New England Biolabs) o/n at 37◦C and subjected to slow agarose
gelelectrophoresis (1% agarose (w/v), TAE buffer, 30V, o/n) as described (Subsection
4.1.2). Gel preparation prior to membrane transfer included depurination in 0.25M HCl,
denaturation in buffer I (1.5M NaCl, 0.5M NaOH), and gel neutralization in buffer II
(1M Tris base, 1.5M NaCl) (pH7.4). O/n transfer of single stranded DNA molecules onto
a positively charged nylon membrane (HYBOND-N+nylon membrane, GE Healthcare)
was based on capillary force. DNA membrane immobilization was mediated by shortwave
ultraviolet energy exposure (254nm, 120J) in a CL-1000 Ultraviolet Crosslinker (UVP).
Specific DNA fragment identification was achieved by membrane hybridization with
a radioactively labeled probe located at the 5′-end of the ROSA26 locus. The probe de-
tects a 4.6kb fragment for the wildtype and an 8.9kb fragment for the recombinant allele.
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For that purpose, 40ng of ROSA26 probe was labeled by incorporation of [α-P32]-dCTP
(Hartman Analytic GmbH) via random priming using the Ready-To-GoTM DNA label-
ing beads (GE Healthcare). Subsequently, the radioactively labeled probe was purified
by Micro SpinTM S-200 HR columns (GE Healthcare) according to the manufacturer’s
instructions. Pre-hybridization (1h, 65◦C) and final radioactive hybridization of the mem-
brane (o/n, 65◦C) were done in Church buffer (1mM EDTA, 0.25M sodium phosphate
buffer (pH7.2), 7% SDS (w/v), 1% BSA (w/v)). This procedure was followed by wash-
ing steps in buffer III (2× SSC, 0.1% SDS (w/v)) and buffer IV (0.2× SSC, 0.1% SDS
(w/v)). Intended counts were below 50 IPS (incidents per second) as measured by a con-
tamination monitor (LB122, Berthold Technologies). For signal detection the hybridized
membrane was exposed to a phosphor storage screen (GE Healthcare) o/n, which is able
to chemically trap radioactive energy. Upon red laser excitation in a PhosphorImagerTM
(Molecular Dynamics) the radioactive energy is released as emitted light, being propor-
tional to the amount of radioactively labeled genomic DNA present on the membrane.
Data were analyzed by using ImageQuantTM software.
Primer sequences (probe fwd/probe rev) used for probe amplification were kindly
provided by M. Schmidt-Supprian (Max Planck Institute for Biochemistry, Molecular
Immunology & Signal Transduction, Munich), and are listed in Subsection 3.3.2. Cycling
conditions for generating a 607bp product were as follows: 98◦C for 30s, 35 cycles of 98◦C
for 10s, 53.5◦C for 30s, 72◦C for 15s, and an end-elongation step at 72◦C for 10min. The
Physion Hot Start High Fidelity DNA Polymerase (Finnzymes) was used for amplification
with a standard reaction set-up as described in Subsection 4.1.3.
4.2 Work with Proteins
4.2.1 Westernblot Analysis
For whole cell protein analysis 5×106 retrovirally infected JurkatE T cells or 1×107
primary lymphocytes were lysed in ice-cold CHAPS buffer (10mM Tris (pH7.5), 1mM
MgCl2, 1mM EGTA, 10% glycerol (v/v), 0.5% CHAPS (w/v)), supplemented with phos-
phatase (50mM NaF, 0.1mM Na3VO4, 10mM β-glycerophosphate) and protease (Com-
plete EDTA free Protease Inhibitor Cocktail Tablets, Roche Diagnostics) inhibitors. Pro-
tein concentrations were spectrophotometrically determined. This is based on a coomassie
brilliant blue G-250 dye/protein interaction, which causes a shift in the adsorption
maximum from 465nm to 595nm wavelength [21]. Cell lysates were subsequently sub-
jected to standard westernblot analysis [29]. To this end, proteins were denaturated in
SDS sample buffer (62.5mM Tris/HCl (pH6.8), 2% SDS (w/v), 10% glycerol (v/v), 5%
2-mercaptoethanol (v/v), 0.02% bromphenol blue (w/v)) and incubated at 95◦C for 5min
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before loading. Polyacrylamid gel electrophoresis with a discontinous buffer system was
applied to separate proteins according to their molecular weight and SDS negativity [104].
A standard gel run was performed in a SDS-PAGE running buffer (25mM Tris (pH 8.3),
2M glycine, 1% SDS (w/v)) at 130-145V. Hence, the resolved proteins were transferred
electrophoretically onto a PVDF (Amersham HybondTM -P, GE Healthcare) or nitrocellu-
lose (Protan R© Nitrocellulose, Whatman R©) membrane via a semi-dry blotting approach
in transfer buffer (50mM Tris (pH 8.5), 40mM glycine, 0.03% SDS (w/v), 20% methanol
(v/v) added prior to use). Membranes were probed with antigen specific primary anti-
bodies (dilution range 1:1000–1:2000). Antibody dilutions were prepared in 5% skim milk
powder (w/v) or 5% BSA (w/v) in TBST (0.025% Tween-20 (v/v), 20mM Tris (pH7.4),
137mM NaCl). For chemiluminesence-based detection, HRP-conjugated secondary anti-
bodies (dilution 1:2000) and detection systems LumigenTM TMA-6, Solution A+B (GE
Healthcare) or Detection Reagent 1+2/Peroxid Solution (Thermo Scientific, Pierce) were
applied. The applied antibody panel is summarized in Subsection 3.2.1.
4.2.2 Lipid Raft Preparations
Lipid raft fractionation was based on sucrose gradient centrifugation and applied as de-
scribed [206]. In brief, 5×107 purified lymphocytes were stimulated or kept unstimu-
lated and lysed in 1ml ice-cold Brij lysis buffer (1% Brij97 (v/v), 150mM NaCl, 20mM
Tris (pH7.5), 2mM EDTA, 10mM NaF, 1mM Na3VO4, protease inhibitors (Complete
Protease Inhibitor Cocktail tablets, Roche Diagnostics)), and prepared by dounce ho-
mogenization. Alternatively, 1×107 JurkatE T cells were harvested 36h post retroviral
infection, stimulated, or kept unstimulated and prepared equally. For stimulation settings
see Subsection 4.4.5. Historically described as non-ionic, detergent-resistant, cholesterol
and glycosphingolipid enriched areas within the membrane lipid bilayer [25], lipid rafts
remain intact during the applied lysis procedure. After centrifugation (2000rpm, 10min,
4◦C) post-nuclear supernatants were mixed with an equal volume of 85% (w/v) sucrose,
overlaid with 2ml of 35% (w/v) and 1ml of 5% (w/v) sucrose and separated according
to their density by ultracentrifugation (Beckman SW41 Rotor, 200 000g, 4◦C, 16h). Su-
crose solutions were prepared in MES-buffered saline (25mM MES (pH6.5), 150mM NaCl,
5mM EDTA). Eleven 400µl fractions were harvested from the top of the gradient. Due
to low amounts, raft-associated protein was concentrated with 10% trichloroacetic acid
precipitation [159]. Both raft-associated protein (enriched from fraction 1-4) and non-raft
protein (fraction 9-11) were resuspended in SDS sample buffer, pooled, and subjected to
westernblot analysis (Subsection 4.2.1). Nitrocellulose membrane (Protan R©Nitrocellulose,
Whatman R©) was used for protein blotting. Successful raft separation was confirmed from
the collected gradient fractions 1-4 via chemiluminescence-based dot-blot analysis, visual-
izing the lipid raft associated ganglioside GM1 by interaction with the HRP labeled cholera
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toxin B subunit (Sigma-Aldrich) [192]. Detection systems were applied as described for
westernblot analysis (Subsection 4.2.1). Lipid raft experiments were performed together
with Dr. Uta Ferch (former member of the lab).
4.3 Work with Retroviruses
4.3.1 Retroviral Expression Vectors
Retroviral constructs were generated by cloning the ITK-SYK cDNA into the MSCV-
based vector pMigR1 [137]. As a special feature, this vector carries the coding sequence
for the enhanced green fluorescent protein (eGFP), preceded by an internal ribosomal
entry site (IRES). eGFP expression therefore enables convenient cell tracking via green
fluorescence. Prior to vector generation, the human ITK-SYK fusion cDNA was created
in a multistep PCR. On the one hand, the N-terminal fragment of the ITK-SYK cDNA,
which encodes the first 165 amino acids of ITK (NM 005546, exon 1–5) was amplified from
JurkatE T cell cDNA. On the other hand, the C-terminal fragment of ITK-SYK which en-
codes the last 330 amino acids of SYK (NM 003177, exon 9–14) was amplified from SuDL6
B cell cDNA. In a subsequent reaction both fragments were annealed at the overlapping
breakpoint sequence. Amplified full-length ITK-SYK cDNA was then used for molecu-
lar cloning as described (Subsection 4.1.6). The primer pair is xhoI fwd/itk rev overlap
and the primer pair syk fwd overlap/is ecoRI rev were used respectively for amplifying
the N-terminal ITK (520bp) and the C-terminal SYK (1027bp) fragment. Amplification
conditions for both fragments were 98◦C for 30s, 35 cycles of 98◦C for 10s, 65.6◦C for 20s,
72◦C for 20s followed by an end-elongation step at 72◦C for 10min.
Individual fragments were purified as described (Subsection 4.1.6) and annealed
by the following reaction cycles: 98◦C for 30s, 8 cycles of 98◦C for 10s, 80◦C for 30s,
72◦C for 48s, and 98◦C for 30s. Amplification of the full-length XhoI/EcoRI -flanked
ITK-SYK cDNA (1514bp) was obtained by running 22 cycles of 98◦C for 10s, 61◦C
for 30s, 72◦C for 30s, and an end-elongation step of 72◦C for 10min, with the flank-
ing primer pair is xhoI fwd/is ecoRI rev. The Physion Hot Start High Fidelity DNA
Polymerase (Finnzymes) was used in all reactions. Reactions were set-up as described
(Subsection 4.1.3). Primer sequences used for individual amplifications are summarized in
Subsection 3.3.1. Sequencing of the cloned TOPOXhoI−ITK−SY K−EcoRI vector confirmed
the correct fusion cDNA [178]. The sequence had been additionally verified by align-
ment with the ITK-SYK cDNA generated directly from patient-derived RNA (provided
by Berthold Streubel, Department of Pathology, Medical University of Vienna, Austria).
Hence, XhoI/EcoRI -flanked ITK-SYK cDNA was hence available for cloning into pMigR1
as described (Subsection 4.1.6).
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Retroviral constructs expressing the aminoacid exchange mutants ITK-SYK (K262R)
(ITK-SYKKD) and ITK-SYK (R29C) (ITK-SYKPHmut) were generated from the tem-
plate MigR1ITK−SY K by applying the Quick Change R© Site-Directed Mutagenesis Kit
(Stratagene). The procedure was performed according to the manufacturer’s instruc-
tions. This approach combines PCR amplification, using oligonucleotide primers carry-
ing the mutation of interest, with a methylation selective DNA digest. The use of DpnI
(Roche), a RE which specifically targets methylated DNA, enables propagation of the
newly synthesized, non-methylated plasmid DNA in competent bacteria. In brief, 5ng
of pMigR1ITK−SY K vector template was amplified by adding 0.05U/µl Pfu Turbo DNA
polymerase (Stratagene), 0.2mM dNTP each (Bioline) and 125ng primer each in the sup-
plied reaction buffer (Stratagene), with a total reaction volume of 50µl. The primer pairs
is kd fwd/is kd rev and is ph fwd/is ph rev were chosen to generate pMigR1ITK−SY K−KD
and pMigR1ITK−SY K−PHmut, respectively. The applied PCR conditions were 95◦C for 30s,
12 cycles of 95◦C for 30s, 55◦C for 60s, 68◦C for 8min followed by a 2min incubation on
ice. For digest of the parental plasmid DNA, 0.2U/µl DpnI (Roche) were added, and incu-
bated for 1h at 37◦C. Transformation of XL1-Blue supercompetent cells (Stratagene) with
the newly generated plasmid DNA was done according to the manufacturer’s instructions.
Primer sequences used for site-directed mutagenesis are summarized in Subsection 3.3.1.
4.3.2 Retroviral Transduction
Retroviral transduction is the process of transferring genetic material to host cells by
retroviruses. Early steps of retroviral transduction include virus adsorption and inter-
action of viral proteins, such as the envelope protein with host cell surface receptors,
eventually triggering virus/cell membrane fusion [35]. In the case of ecotropic viruses, the
host cell membrane receptor is a cationic amino acid transporter, designated mCAT-1,
which is expressed selectively on murine and rat cells [6, 195, 92]. Infection of human
cells nevertheless becomes possible when choosing cell lines which have been genetically
modified to express the murine ecotropic retroviral receptor on their cell surface, such as
JurkatE T cells [76]. Thus, a naturally host-restricted MSCV-based virus can be applied
to transduce a human cell line. Applying this system, retroviral particles were produced
by transiently transfecting the PhoenixE packaging cell line with the indicated retroviral
expression vectors (Subsection 4.3.1) via the CaPO4 precipitate method [69]. PhoenixE in
itself carry the viral genes gag, pol, and env needed for retroviral particle assembly [85].
In practice, 12h prior to transfection, 2.5×106 PhoenixE cells were seeded per
10cm plate in transfection medium (TM) (DMEM, 10% FBS (v/v), 1% penicillin
(pen)/streptomycin (step) (v/v)) to achieve a 50–70% cell confluence on the day of trans-
fection. Pretreatment of PhoenixE consisted of a 30min incubation step in TM supple-
mented with 40µM chloroquine. Chloroquine enhances the transfection efficiency by in-
CHAPTER 4. METHODS 37
creasing the intralysosomal pH, thus reducing enzymatic degradation of internalized retro-
viral DNA [119]. In parallel, 2µg of the respective retroviral expression vector was mixed
with 125mM CaCl2 in HBS buffer (140mM NaCl, 0.75mM Na2HPO4, 25mM HEPES
(pH6.93)), and incubated at RT for 15min. Formed DNA/CaCl2 precipitates were then
added dropwise to chloroquine-pretreated PhoenixE cells followed by a change of medium
after 6h of incubation. Virus-containing supernatant was collected 48h and 72h post trans-
fection, filtered (Millex R©-HV Filter, 0.45µm), and stored at 4◦C until used. For retro-
viral transduction 0.5×106 JurkatE T cells/ml were resuspended in viral supernatant,
supplemented with 25mM HEPES and 10µM polybrene (MilliporeTM ). Polybrene, as
cationic polymer, enhances initial viral adsorption and improves transduction efficiency
[39]. JurkatE T cells were then subjected to one round of spin infection by centrifugation
(2400rpm, 32◦C, 90min), and cultured for 12h before changing the medium and seeding
for further analysis. Transduction efficiency was determined flow cytometrically, and was
based on the percentage of eGFP+ viable JurkatE T cells in culture. PhoenixE cells and
JurkatE T cells were kindly provided by Garry P. Nolan (Department of Microbiology and
Immunology, Stanford University, USA) and kept under standard cell culture conditions
as described (Subsection 4.4.1).
4.4 Work with Eukaryotic Cells
4.4.1 Basic Cell Culture
JurkatE T cells were cultured in RPMI-1640 medium supplemented with 10% FBS (v/v)
(Hyclone Perbio), 1% L-glutamine (v/v), 1% pen/step (v/v) and 0.1% 2-mercaptoethanol
(v/v) at a density of 0.1×106 cells/ml and splitted at a density of 0.5×106 cells/ml.
PhoenixE packaging cells were maintained in DMEM, supplemented as described for
JurkatE T cells, seeded at 2×106 cells per 10cm plate, and splitted at a ratio of 1:5 every
second day by trypsinization (1% Trypsin/EDTA (v/v)). Primary lymphocytes were kept
in RPMI-1640, supplemented with 5% FBS (v/v), 1% L-glutamine (v/v), 1% pen/step
(v/v), and 0.1% 2-mercaptoethanol (v/v) until analyzed. All cells were cultivated under
standard cell culture conditions at 37◦C, 5% CO2, and a relative humidity of 95%. Cells
were counted by light microscopy under consideration of cell viability as assessed by
trypan blue (Trypan Blue Stain 0.4%(w/v), Gibco R©) exclusion. For conservation, cells
were kept in either RPMI or DMEM, depending on the cell line, supplemented with 10%
DMSO (v/v)/10% FBS (v/v) and stored in liquid nitrogen. Medium and supplements
other than FBS were purchased from Gibco R©, and tissue culture labware was purchased
from TPP R© Techno Plastic Products AG or BD FalconTM . For functional studies, the
SYK inhibitor R406 (provided by Rigel Pharmaceuticals, San Francisco, USA) was added
CHAPTER 4. METHODS 38
to the cell culture medium at a concentration of 2µM where indicated.
4.4.2 Embryonic Stem Cell Culture
E14K embryonic stem cells (ESCs), derived from the mouse strain 129P2/OlaHsd
[169], were cultured in ESC medium (DMEM supplemented with 15% FBS (v/v), 1%
leukemia inhibitory factor (LIF) (v/v), 1% L-glutamine (v/v), 1% pen/strep (v/v), 0.1%
2-mercaptoethanol (v/v), and grown on a monolayer of murine embryonic fibroblasts
(feeder cells). ESCs were passaged onto feeder cells every second day with a splitting ratio
of 1:4–1:6, emphasizing to dissociate ESC colonies into single cells after trypsinization by
thorough pipetting. ESC medium was changed daily. Monitoring of colony density and
morphology was performed microscopically to control ESC quality. Cell culture on feeder
monolayers as well as the addition of LIF to the ESC cell culture medium [198] were
used as standard practice to prevent ESC differentiation processes, and to maintain their
totipotency required for germline transmission [183].
Feeder cells were routinely cultured in FC medium (DMEM supplemented with 5%
FBS (v/v), 1% pen/strep (v/v), 1% L-glutamine (v/v), 0.1% 2-mercaptoethanol (v/v),
and passaged every second day with a splitting factor of 1:2. Cells were pretreated for
2h with mitomycin C containing FC medium (f.c. 10µg/ml) when seeded as monolayer
for ESC propagation. Mitomycin C acts as an alkylating antibiotic and renders cells
mitotically inactive by forming DNA crosslinks [182]. All cells were kept under standard
cell culture conditions (Subsection 4.4.1). Supplements were approved for stem cell culture,
and purchased from Biochrom AG. FBS was purchased from PAN-Biotech, and media
was purchased from Gibco. Tissue culture labware was purchased from BD FalconTM .
LIF and feeder cells were kindly provided by the lab of Tim Sparwasser (Institute for
Infection Immunology, Twincore Center, Hannover, Germany).
4.4.3 Embryonic Stem Cell Electroporation and Selection
Electroporation was applied as a transformation technique to introduce the targeting
vector pROSA26loxSTOP lox−ITK−SY K into murine E14K ESCs. This method utilizes pulsed
electric current to induce transient permeabilizations within the phospholipid bilayer of
eukaryotic cells [133], facillitating the transport of genetic material into the target cell. To
this end, a surplus of 50µg of pROSA26loxSTOP lox−ITK−SY K targeting vector was linearized
per electroporation by incubation with 0.4U/µl SnaBI (New England Biolabs) o/n at
37◦C. Linearized DNA was purified by phenol/chloroform precipitation [159] and dissolved
in PBS under sterile conditions. Per electroporation, 5×106 E14K ESCs were mixed with
20µg of linearized targeting vector in 800µl of ESC medium (Subsection 4.4.2), transferred
to a Gene Pulser Cuvette (0.4cm electrode gap, Bio-Rad Laboratories) and electroporated
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at 250µF, 0.34V in a GenePulserTM electroporator (Bio-Rad Laboratories). Shocked cells
were incubated for 3min at RT, followed by a 15min resting phase on ice, before being
seeded on feeder cell monolayers as described (Subsection 4.4.2).
Stem cell selection was performed by Geneticin R© (Invitrogen) treatment
(f.c. 200µg/ml in ESC medium) for ten days, with a change of selection medium
every second day. Geneticin R© is a gentamicin-related amino glycoside which in-
terferes with 80S ribosome function in eukaryotic cells [14], ultimately leading to
cell death [36]. Notably, ESCs carrying the neo cassette which originated from the
pROSA26loxSTOP lox−ITK−SY K targeting vector, will express the bacterial neomycin resis-
tance gene. It encodes for the amino glycoside 3′-phosphotransferase (APH) II [15]. These
cells become Geneticin R©-resistant and survive the ten day treatment. Subsequently, resis-
tant ESC colonies were harvested under a stereomicroscope (MZ75, Leica Microsystems)
and cultivated individually in 96-well plates according to stem cell culture conditions
(Subsection 4.4.2). In total, four rounds of electroporation were performed, and eventu-
ally forty-two E14K clones with best morphology selected, propagated and analyzed for
recombination at the ROSA26 locus by southernblot analysis (Subsection 4.1.7).
4.4.4 Cell Purification
Enrichment of cell populations was either achieved by density gradient centrifugation or
by cell type specific purification via magnetic beads. Prior to either procedure, individual
organs were mashed, and harvested cells were subjected to red blood cell (RBC) lysis by
resuspension in 1ml of RBC Lysis Buffer (eBioscience). This was followed by an incubation
step at RT for 5min. Lastly, primary cells were washed in cell culture medium (Subsection
4.4.1) and further processed.
For protein analysis, primary T cells or B cells were purified from pooled spleen
(SPL) and lymph node (LN) cell suspensions firstly by depletion of myeloid cells with
α-CD11b (M1/70; BD Pharmingen) and Dynabeads R©M-450 sheep α-rat IgG. Secondly,
depletion of either B cells or T cells with either Dynabeads R© mouse panT (Thy1.2)
or mouse panB (B220) was performed. Bead-bound cells were separated by a magnetic
field. Untouched cells of interest were collected from the flow-through by centrifugation
(300g, 5min, 4◦C). All magnetic beads were purchased from Invitrogen. Primary total
lymphocytes from organs such as liver (LIV), lung (LNG) and kidney (KID) were en-
riched by Percoll (Biochrom AG) density gradient centrifugation [138] prior to flow cyto-
metric analysis (Subsection 4.4.7). Primary cells were resuspended in a 40% Percoll/PBS
solution, carefully underlaid with an 80% Percoll/PBS solution, and subjected to cen-
trifugation (2600rpm, 25min, 20◦C, no brake). Mononuclear cells were collected from the
40/80 interface, washed in cell culture medium and prepared for further analysis.
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4.4.5 Cell Stimulation
Cell stimulation of primary T cells and JurkatE T cells was based on antibody binding
to the CD3ǫ molecule of the TCR complex and the costimulatory molecule CD28, with
or without crosslinking of the primary antibodies.
For lipid raft preparations, 5×107 purified T cells were resuspended in resting medium
(RM) (RPMI-1640, 0.2% BSA (w/v), 0.1% 2-mercaptoethanol (v/v)) and incubated for 1h
at 37◦C in a water bath. Functional grade purified α-mouse CD3e (f.c. 5µg/ml, 145-2C11,
eBioscience) and α-mouse CD28 (f.c 1µg/ml, 37.51, eBioscience) antibody were added.
Subsequently, cells were incubated on ice for 20min, spun down (425g, 3 min, 4◦C), resus-
pended in prewarmed AffiniPure rabbit α-syrian hamster IgG (H+L) cross-linking anti-
body (f.c. 1µg/ml, Jackson ImmunoResearch), and incubated for 5min at 37◦C in a water
bath. Stimulation of 1×107 retrovirally infected JurkatE T cells was carried out as out-
lined for primary T cells. In this regard, however, the functional grade purified α-human
CD3 (f.c. 5µg/ml, 145-2C4, BD Pharmingen), α-human CD28 (f.c. 1µg/ml CD28.2, BD
Pharmingen) antibody and the AffiniPure goat α-mouse IgG (H+L) (f.c 1µg/ml, Jackson
ImmunoResearch) cross-linking antibody were used. Stimulation of JurkatE T cells was
performed 36h after retroviral infection. Lipid raft preparation was performed as described
(Subsection 4.2.2). For all stimulations, primary and cross-linking antibodies were diluted
in RM. Mice older than 12 weeks were used for T cell preparations to obtain sufficient
numbers of ITK-SYK expressing T lymphocytes.
For analyzing CD69 surface expression and IL-2 production, retrovirally infected
JurkatE T cells were adjusted to a concentration of 1×106 cells/ml in cell culture medium
(Subsection 4.4.1) and kept under standard cell culture conditions for 12h prior to stim-
ulation. The latter occured with platebound α-human CD3 (f.c. 10µg/ml, HIT3a, BD
Pharmingen) and soluble α-human CD28 antibody (f.c. 2µg/ml, CD28.2, BD Pharmin-
gen), diluted in cell culture medium, respectively. CD3 immobilization was achieved by
preincubating the wells of flat bottom plates with AffiniPure goat α-mouse IgG (H+L)
antibody (f.c. 10µg/ml in PBS, Jackson ImmunoResearch) o/n at 4◦C. Supernatants were
harvested 24h post stimulation and IL-2 concentrations were determined via ELISA (Sub-
section 4.4.6). CD69 surface expression was determined 24h and 48h post stimulation via
flow cytometry (Subsection 4.4.7).
For phosflow analysis (Subsection 4.4.7), retrovirally infected JurkatE T cells were
adjusted to a concentration of 5×106 cells/ml in RPMI-1640 supplemented with 1% FBS
(v/v) and 0.1% 2-mercaptoethanol, and subsequently rested on ice for 30min. Purified
α-human CD3 (f.c. 5µg/ml, HIT3a, BD Pharmingen) and α-human CD28 antibody (f.c.
1µg/ml, CD28.2, BD Pharmingen) were added. Cells were incubated (rolling) at 4◦C for
20min, spun down (425g, 3min, 4◦C), and resuspended in prewarmed AffiniPure goat
α-mouse IgG (H+L) (f.c. 1µg/ml, Jackson ImmunoResearch) cross-linking antibody, fol-
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lowed by a 5min incubation step at 37◦C in a water bath. Primary antibodies and the
cross-linking antibody were diluted in RPMI-1640 supplemented with 1% FBS (v/v) and
0.1% 2-mercaptoethanol. For all individual approaches, stimulations were terminated by
adding ice-cold PBS. Cells were further processed depending on the method applied.
4.4.6 Enzyme-linked Immunosorbent Assay
The immunological technique of enzyme-linked immunosorbent assay (ELISA) employs
the principle of specific antigen/antibody interaction combined with chemiluminescent
detection systems. IL-2 concentrations in cell supernatants from retrovirally-infected
JurkatE T cells, kept unstimulated or stimulated (Subsection 4.4.5), were determined
via the OptEIA Human IL-2 ELISA Set (BD Pharmingen), according to the manufac-
turer’s instructions. In brief, IL-2 was captured via plate bound antigen specific antibody
(α-human IL-2, dilution ratio 1:250) and detected by a soluble biotinylated α-IL-2 specific
antibody (detection antibody: α-human IL-2, dilution ratio 1:250). Biotin/streptavidin
interaction, as strong non-covalent biological interactions [32], was utilized to target en-
zymatic HRP activity to the site of specific antigen/antibody interaction. HRP-mediated
conversion of 3′, 3′, 5′, 5′-tetramethylbenzidine (TMB) under the presence of hydrogen
peroxide, yielded a blue colored oxidized form of TMB. Substrate turnover was terminated
by the addition of 2N H2SO4. The resulting color change to yellow was spectrophotomet-
rically detected at a wavelength of 450nm and correlated to IL-2 concentrations present
in the cell supernatant.
4.4.7 Flow Cytometry
Immunophenotyping of cell populations was done by flow cytometry. This method allows
cell distinction according to its cell size, granularity, cell surface marker expression, and
various intracellular targets using fluorescently labeled antibodies. Light scatter and fluo-
rescence signals emitted after laser excitation are detected, amplified, and converted into
electrical signals, which are then processed on the computer [116].
Primary cell suspensions from thymus (THY), SPL, LN, bone marrow (BM) and pe-
ripheral blood were subjected to RBC lysis (Subsection 4.4.4). Cells were directly used for
flow cytometric staining, whereas cell suspensions from LIV, KID or LNG were addition-
ally purified by Percoll gradient centrifugation (Subsection 4.4.4) prior to cell staining.
For extracellular staining, 0.7×106 cells were resuspended in FACS buffer (FB) (PBS, 3%
FBS), spun down (400g, 5min, 4◦C) and pre-incubated with purified α-mouse CD16/32
antibody (dilution ratio 1:200 in FB, eBioscience) for blocking accessible Fc receptor bind-
ing sites. Subsequent extracellular staining was performed in a total volume of 100µl FB
for 20min at 4◦C, with a final washing step in FB before analysis. Cell activation of retro-
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virally infected JurkatE T cell was assessed by surface staining with the α-human CD69
antibody (FN50) (diluation ratio 1:50 in FB). Fluorescently labeled antibodies against
murine epitopes were used at a 1:200 or 1:400 dilution ratio in FB. Subsection 3.2.3 gives
an overview of antibodies applied for extracellular staining. Data were acquired either on
a FACSCaliburTM or a FACSCantoIITM flow cytometer.
Activation of retrovirally infected JukatE T cells was analyzed via intracellular stain-
ing with phospho-specific antibodies (phosflow). For that purpose, cells were treated with
2% PFA for fixation followed by membrane permeabilization with 70% ice-cold methanol
as described [165]. Viability distinction was realized by staining with an amine-reactive
dye (violet Live/Dead, Invitrogen). Subsection 3.2.4 summarizes the phospho-specific flu-
orescently labeled antibodies applied (dilution ratio 1:10 in FB). Data acquisition was
carried out on a LSRII flow cytometer. Fluorescently labeled antibodies were purchased
from either BD Biosciences or eBioscience. All flow cytometers were purchased from BD
Biosciences. FlowJo software (Tree Star, Inc.) was used for data analysis. Phosflow analy-
sis was performed together with Marc Schweneker (former member of the lab) and Julian
Holch (medical student in the lab).
4.5 Work with Mice
4.5.1 Mouse Husbandry
All animals were housed under standardized, specific pathogen free conditions in individ-
ually ventilated cages (Thoren MaxiMiser R© caging systems or TechniPlast IVC). Studies
were conducted in compliance to federal and institutional guidelines. Animal protocols
were approved by the government of Upper Bavaria.
4.5.2 Generation of ROSA26loxSTOPlox−ITK−SYK Mice
Conditional gene targeting at the ROSA26 locus was chosen to generate mice with ubiqui-
tous expression of a loxSTOPlox-ITK-SYK-eGFP fusion transcript. The newly generated
mouse strain is termed ROSA26loxSTOP lox−ITK−SY K . Due to the loxP-site flanked STOP
cassette positioned upstream of the ITK-SYK and eGFP coding sequences, expression of
both proteins is blocked and only realized upon breeding to Cre-transgenic mouse strains
(Subsection 4.5.3).
Starting point for creating the ROSA26loxSTOP lox−ITK−SY K mouse strain was the
generation of the fusion ITK-SYK cDNA via overlap PCR as described (Subsection
4.3.1). A final amplification step with the primer pair is fwd ascI/is rev ascI produced an
AscI -flanked ITK-SYK cDNA (1523bp) product. Notably, the forward primer contained
a Kosaq consensus sequence (CCACC) [96] directly positioned upstream of the ITK-SYK
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cDNA start codon for optimal translational initiation. The PCR conditions were 98◦C for
30s, 35 cycles at 98◦C for 10s, 65.6◦C for 30s, 72◦C for 48s with an end-elongation step at
72◦C for 10min. The Physion Hot Start High Fidelity DNA Polymerase (Finnzymes) was
used for amplification with a standard reaction set-up as described (Subsection 4.1.3).
Primer sequences are outlined in Subsection 3.3.1.
The ITK-SYK amplicate was introduced into the pCR R©II-TOPO R© vector, sequence
verified, and upon AscI -digestion was cloned into the core pROSA26 targeting vector
[160]. The vector was kindly provided by Marc Schmidt-Supprian (Max Planck Insti-
tute for Biochemistry, Molecular Immunology & Signal Transduction, Munich, Germany).
Correct orientation of the ITK-SYK insert was determined by RE digest and subsequent
vector sequencing. Hence, the SnaBI -linearized pROSA26loxSTOP lox−ITK−SY K targeting
vector was introduced into E14K ESCs by electroporation. Geneticin R© treatment was
used for positive stem cell selection as described (Subsection 4.4.3). Geneticin-resistant
clones were screened by southernblot analysis for recombination at the ROSA26 locus
(Subsection 4.1.7). ESC clones with best morphology and growth characteristics were in-
jected into C57BL6/J blastocysts and subsequently transferred to pseudopregnant foster
mice as described [183]. Two independent clones gave rise to chimeric offspring, which after
breeding with C57BL/6 mice eventually generated ROSA26loxSTOP lox−ITK−SY K heterozy-
gous mice. Germline transmission of the targeted ROSA26 allele was verified by PCR
of tail DNA from agouti coat colored F1 offspring mice (Subsection 4.5.4). Blastocyst
microinjection was carried out by Susanne Weiss in collaboration with Tim Sparwasser
(Institute for Infection Immunology, Twincore Center, Hannover, Germany).
4.5.3 Mouse Breeding Approaches
In order to achieve cell type specific expression of ITK-SYK, ROSA26loxSTOP lox−ITK−SY K
mice were bred to individual Cre-transgenic mouse strains. Within these mice the Cre
recombinase expression is put under the control of a lineage specific promoter. Thus,
for T cell specific expression of the fusion kinase, ROSA26loxSTOP lox−ITK−SY K mice were
crossed with CD4-Cre [108] mice. For B cell specific expression crossing with CD19-Cre
mice [150] took place. The resulting mouse strains are referred to as ITK-SYKCD4−Cre
and ITK-SYKCD19−Cre , respectively. All mice were of mixed C57BL/6 and 129P2/OlaHsd
genetic background. If not stated otherwise, littermates were used in all experiments.
4.5.4 Genotyping
Mouse progeny were identified through amplification of strain-specific sequences at the
recombinant locus. For that purpose, genomic DNA was extracted from tail pieces apply-
ing the Wizard SV Genomic DNA Purification System (Promega). The targeted ROSA26
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locus was identified with the primer pair geno is fwd/geno is rev, yielding a 569bp frag-
ment for the recombinant locus. The PCR conditions were 95◦C for 5sec, 30 cycles of 95◦C
for 30s, 58◦C for 30s, 72◦C for 34s, and an end-elongation step at 72◦C for 10min. The
Cre allele from CD4-Cre mice [108] was identified with the primer pair Cre fwd/Cre rev,
yielding a 200bp fragment for the recombinant locus. The PCR conditions were 95◦C for
2s, 15 cycles of 95◦C for 30s, 64◦C for 30s, 72◦C for 30s followed by 20 cycles of 95◦C
for 30s, 58◦C for 30s, 72◦C for 30s, as well as an end-elongation step at 72◦C for 10min.
The Cre allele originating from CD19-Cre mice [150] was amplified by using the primers
Cre7/CD19c/CD19d. The PCR conditions were 95◦C for 2s, 30 cycles of 95◦C for 45s,
57◦C for 45s, 72◦C for 50s, and an end-elongation step at 72◦C for 10min. A 492bp frag-
ment was amplified for the wildtype and a 715bp fragment for the recombinant locus,
respectively.
PCR reaction set-ups were performed as described (Subsection 4.1.3). All genotyp-
ing reactions were carried out with the Illustra Taq DNA Polymerase (GE Healthcare).
Product separation was achieved by agarose gelelectrophoresis (Subsection 4.1.2). Primer
sequences are summarized in Subsection 3.3.3.
4.5.5 Transplantation
Transplantation experiments have been performed to analyze the oncogenic potential of
ITK-SYK expressing primary T cells in vivo. For that purpose, 6 week old Hsd:Athymic
Nude-Foxn1nu mice [56, 136] were intravenously injected with 1.5×107 splenocytes isolated
from diseased ITK-SYKCD4−Cre mice. Splenocytes were subjected to RBC lysis and resus-
pended in 200µl sterile PBS (Gibco) prior to injection. Recipients were daily monitored
for signs of disease such as weight loss, hunched posture and extended abdomen. Blood
samples were regularly analyzed by flow cytometry (Subsection 4.4.7) at the indicated
timepoints. Blood sampling was performed as described [68]. Hsd:Athymic Nude-Foxn1nu
mice were purchased from Harlan Netherlands B.V.
4.5.6 Histology
Histological analysis had been done in collaboration with Dr. Leticia Quintanilla-Fend
(Institute for Pathology, University of Tuebingen, Germany) and performed as previously
described [100]. In brief, organs were fixed in 4% formaldehyde and embedded in paraf-
fin. Sections (3–5µm) were cut and cell nuclei were visualized by haematoxylin staining,
followed by counterstaining with eosin for cellular detail (H&E staining). To specify and
characterize cell types involved in mouse pathology, immunohistochemistry was performed
on an automated immunostainer (Ventana Medical System Inc., Tuscan, Ariz.) according
to the company’s protocols. The applied primary antibody panel is summarized in Sub-
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section 3.2.5. For all systems applied (Basic DAB/iVIEW DAB detection kit (Ventana
Medical System, Inc., Tucson, AZ), and ABC-Kit (Vector, Burlingame, Canada)), epitope
detection was indirect via HRP-linked secondary antibodies.
4.6 Statistical Analysis
Where indicated, results were analyzed for statistical significance with the unpaired
two-tailed Student’s t test. Differences between groups were considered as significant at
p-values <0.05. Statistical analysis has been performed with Prism Version 4.0a Graph-
Pad Software, Inc.
Chapter 5
Results
5.1 ITK-SYK Expression Leads to T Cell Activation
In Vitro
The chromosomal translocation t(5;9)(q33;q22) was originally described in a subgroup of
patients with PTCL-NOS. The translocation results in the generation of a novel transcript
which encodes for the non receptor tyrosine fusion kinase ITK-SYK [178].
To gain first insights into ITK-SYK functionality and its potential role in aberrant
signaling, a set of retroviral transduction experiments were performed. Jurkat T cells,
which are commonly used to study T cell receptor signaling [1], were chosen as a cellu-
lar system. Specifically, JurkatE T cells express the ecotropic murine viral receptor [76]
which allows the infection with MSCV-based retroviruses. To generate retroviral expres-
sion vectors, ITK-SYK cDNA was cloned into the pMigR1 vector. It contains an internal
ribosomal entry site (IRES) as well as the coding sequence for the enhanced green fluo-
rescent protein (eGFP) [137]. The expression of eGFP permitted convenient tracking of
retrovirally infected cells by flow cytometry. ITK-SYK functionality was further studied
by generating retroviral vectors expressing ITK-SYK protein mutants. To investigate the
importance of ITK-SYK kinase activity, an amino acid exchange of lysine to arginine at
position 262 (K262R) was introduced by site directed mutagenesis (nucleotide exchange:
AAA⇒AGA). This exchange rendered a kinase dead mutant of ITK-SYK (ITK-SYKKD)
by destroying the ATP binding site in the catalytic center of the SYK derived kinase
domain [181]. To analyze the necessity of ITK-SYK membrane recruitment, a PH domain
mutant (ITK-SYKPHmut) was generated by an amino acid exchange of arginine to cysteine
at position 29 (R29C) (nucleotide exchange: CGC⇒TGC). This mutation was described
for the wildtype ITK molecule to abrogate membrane recruitment by destroying its lipid
binding pocket [28]. Figure 5.1 schematically depicts the fusion tyrosine kinase ITK-SYK
and its mutated protein versions.
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ITK-SYK PH TH Kinase
PH TH KinaseITK-SYK
KD
ITK-SYK
PHmut
PH TH Kinase
K262R
R29C
Figure 5.1: Schematic view of the fusion kinase ITK-SYK and its mutants. Red
triangles indicate sites of an amino acid exchange introduced to generate the kinase dead version (ITK-
SYKKD, K262R) and the PH domain mutated version (ITK-SYKPHmut, R29C) of ITK-SYK. Protein
domains are indicated. PH, Pleckstrin homology domain; TH, Tec homology domain; SH2, SRC homology
2 and SH3, SRC homology 3 domain; Kinase, tyrosine kinase domain.
The following in vitro experiments were intended to analyze early ITK-SYK mediated
signaling events. They included the analysis of protein recruitment into lipid rafts, which
have been described as important signal initiation and transduction platforms upon re-
ceptor engagement [113], as well as the analysis of activating protein phosphorylation by
westernblotting and intracellular flow cytometry.
To address the aspect of membrane recruitment, lipid raft as well as non raft fractions
were isolated by sucrose gradient centrifugation from retrovirally infected JurkatE T cells,
expressing wildtype ITK-SYK, ITK-SYKKD or ITK-SYKPHmut. They were subjected to
westernblot analysis with antibodies directed against ITK, total phospho-tyrosine or phos-
phorylated PLCγ1 (pY783). As a negative control, JurkatE T cells were infected with
retrovirus expressing only the eGFP fusion protein (GFP). These cells are subsequently
referred to as control JurkatE T cells. As a positive control to study TCR dependent
signaling events upon receptor engagement, control JurkatE T cells were stimulated with
the agonistic CD3 and CD28 antibodies. As seen in Figure 5.2 A, westernblotting against
ITK showed strong recruitment of the fusion kinase ITK-SYK into the lipid raft fraction
of ITK-SYK expressing JurkatE T cells. ITK-SYK expression resulted in tyrosine phos-
phorylation of raft-associated proteins. Amongst those events, tyrosine phosphorylation
of PLCγ1 was detected, which is known to be a key step in promoting signal transduction
downstream of the TCR [23]. Notably, the observed phosphorylation events as well as
the recruitment of endogenous ITK into the lipid raft fraction after ITK-SYK expression
were both comparable to a TCR stimulatory setting (α-CD3, α-CD28) applied to control
JurkatE T cells. As for the protein domain mutants, ITK-SYKKD was still recruited into
the raft fractions to an equal extent as observed for the wildtype fusion kinase, whereas
membrane recruitment was completely blocked in ITK-SYKPHmut, as expected. Interest-
ingly, expression of neither ITK-SYKKD nor ITK-SYKPHmut induced tyrosine phospho-
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rylation of raft-associated proteins above baseline, although expressed to similar amounts
as seen for the non raft fractions after westernblotting against ITK.
Intracellular flow cytometry was further applied to determine activating protein phos-
phorylation upon ITK-SYK expression. Therefore, retrovirally infected JurkatE T cells
expressing ITK-SYK or eGFP only were stained with phosphospecific antibodies directed
against key proximal as well as downstream positioned signaling molecules involved in
TCR signaling. Levels of phosphorylation in live, transduced (eGFP+) JurkatE T cells,
expressing ITK-SYK (tinted histogram) or eGFP only (untinted histogram) are depicted
in Figure 5.2 B. Histogram overlay analysis showed activating phosphorylation of the
TCR proximal adapter proteins SLP-76 (pY128), LAT (pY171), and of the signal trans-
ducer PLCγ1 (pY783) upon ITK-SYK expression. Increased phosphorylation of the pro-
tein kinase AKT (pS473), as well as the MAP kinases p38 (pT180/pY182) and ERK1/2
(pT202/pY204) were additionally detected. As already observed for lipid raft recruited
proteins, the extent of protein phosphorylation after ITK-SYK expression was similar to
the one seen in control JurkatE T cells stimulated with CD3 and CD28 antibodies (Figure
5.2 C).
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Figure 5.2: ITK-SYK induces signaling events similar to a TCR signal in
vitro. (A) Constitutive ITK-SYK signaling in T cell lipid rafts. JurkatE T cells were infected with
retroviruses carrying ITK-SYK, ITK-SYKKD, ITK-SYKPHmut together with an eGFP or eGFP only as
a control. Lipid raft fractions from unstimulated or α-CD3 (5µg/ml)/α-CD28 (1µg/ml)-stimulated cells
were prepared and subjected to westernblot analysis with antibodies against ITK (top), total phospho-
tyrosine (p-Tyr), or phosphorylated PLCγ1 (p-PLCγ1). Dot blot analysis of the lipid raft marker GM1
confirmed successful raft preparation and equal loading. Data shown are representative of at least two
independent experiments. (B) Phosflow analysis of ITK-SYK mediated signaling. JurkatE T cells were
infected with ITK-SYK together with eGFP (ITK-SYK) or eGFP only (eGFP) expressing retrovirus
and intracellularly stained with activation-specific α-phospho antibodies directed against the indicated
signaling molecules. Signaling was analyzed within the infected viable eGFP+ population as determined
by amine-reactive dye exclusion. Data shown are representative of four independent experiments. (C)
Phosflow analysis of stimulated JurkatE T cells. JurkatE T cells were infected with eGFP only expressing
retroviruses (GFP). Cells were left unstimulated or stimulated for 5min with α-CD3 (5µg/ml)/α-CD28
(1µg/ml) antibody and analyzed as in (B). Results are representative of three independent experiments.
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To investigate the consequences of ITK-SYK related activation on a cellular level,
surface expression of the early activation marker CD69 and production of the autocrine
cytokine IL-2 were assessed, since both events respond to TCR engagement [74, 30]. For
that purpose, retrovirally infected JurkatE T cells expressing the wildtype ITK-SYK,
ITK-SYKKD or ITK-SYKPHmut were analyzed by flow cytometry to determine CD69
expression. Control JurkatE T cells, expressing eGFP only were used as a negative con-
trol. CD3/CD28-stimulated control JurkatE T cells were used as a positive control for
TCR dependent cell activation. Contour blot analysis of gated viable cells showed a clear
surface expression of CD69 in retrovirally transduced cells expressing ITK-SYK, which
was neither observed in JurkatE T cells expressing ITK-SYKKD or ITK-SYKPHmut (Fig-
ure 5.3 A). In agreement with the performed lipid raft experiments, cell activation was
comparable to CD3/CD28-stimulated JurkatE T cells, which expressed CD69 on the cell
surface. Both control JurkatE T cells and non infected cells did not show CD69 expres-
sion as expected. In correlation to the observed cellular activation, ITK-SYK expression
also led to a strong IL-2 production. This is not observed in JurkatE T cells expressing
the ITK-SYKKD or ITK-SYKPHmut mutant (Figure 5.3 B). Amounts of IL-2 measured
in the cell supernatant by ELISA were increased fivefold compared to control JurkatE T
cells subjected to optimal TCR stimulation with CD3/CD28 antibodies. As an additional
approach to substantiate the dependency of ITK-SYK on its kinase activity, retrovirally
transduced JurkatE T cells expressing ITK-SYK were treated with the small molecule
inhibitor R406. It has been shown to R406 blocks wildtype SYK kinase activity in vitro,
while its orally available compound R788 does so in vivo [24]. Both CD69 expression and
IL-2 production was abrogated in the presence of R406 (Figure 5.3 A, B).
From these in vitro experiments it can be concluded that ITK-SYK is a lipid raft-
associated tyrosine kinase, which initiates signaling responses similar to those seen after
TCR engagement. Protein domain mutant analyses showed that ITK-SYK induced sig-
naling is dependent on membrane recruitment and on the functional kinase activity of the
fusion kinase. The later aspect was supported by the fact that ITK-SYK activity could
be blocked upon SYK inhibitor treatment.
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Figure 5.3: ITK-SYK induces cellular outcomes similar to a TCR signal in
vitro. (A) ITK-SYK triggers kinase and PH domain dependent T cell activation. JurkatE T cells were
infected with retroviruses carrying ITK-SYK, ITK-SYKKD, ITK-SYKPHmut together with an eGFP or
eGFP only as a control. Cells were left either unstimulated, stimulated with 10µg/ml α-CD3 and 2µg/ml
α-CD28, or treated with 2µM R406 as indicated and analyzed by flow cytometry. The percentage of
infected eGFP+ CD69-expressing cells from unstimulated, stimulated, or R406-treated cells is indicated.
Data shown are representative of five independent experiments. (B) ITK-SYK induces kinase and PH
domain dependent IL-2 production. JurkatE T cells were infected and treated as in (A). IL-2 concentra-
tions in the cell supernatants were determined by ELISA. Shown are the mean±standard deviation (SD)
from triplicate samples. Data shown are representative of four independent experiments.
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5.2 Mouse Model for Conditional ITK-SYK Expres-
sion
5.2.1 Targeting the ROSA26 Locus
Data gathered from in vitro retroviral transduction experiments suggested a possible
scenario where ITK-SYK is capable of mimicking aspects of a TCR signal, seemingly
doing so without the need for an antigen to be present. Constitutive receptor signaling
might therefore cause cell transformation and eventual T cell lymphoma development.
To study long-term consequences of ITK-SYK expression in vivo, a genetically mod-
ified mouse model was generated. Conditional targeting of the ROSA26 locus was chosen
to achieve cell type specific expression of the fusion kinase ITK-SYK by applying the
Cre/loxP system [72]. The ROSA26 locus has been well characterized and utilized for
knock-in approaches. It is positioned on chromosome 6, consists of three exons, and shows
ubiquitous promoter activity with moderate expression levels [174, 176]. Importantly, ho-
mozygous recombination at the ROSA26 locus does not result in any phenotypical defects
[202] and efficient gene targeting is provided due to high recombination frequencies present
at the chosen locus [174, 59]. For vector generation, the ITK-SYK fusion cDNA was cloned
into a previously described pROSA26 targeting vector upon AscI digestion [160]. To en-
sure optimal translation initiation a consensus CCACC sequence was placed directly in
front of the ITK-SYK start codon [96]. Within the targeting vector, the ITK-SYK cDNA
was positioned downstream of an adenovirus splice acceptor site (SA), followed by a loxP
site flanked neomycin resistance stop cassette (NEO-STOP), and upstream of an FRT site
flanked IRES-eGFP cassette (IRESeGFP), followed by a polyadenylation sequence (pA).
Annealing of the so-called short and long arm of homology, which consisted of identical se-
quences surrounding the site of integration, enabled recombination within intron 1 at the
wildtype (WT) ROSA26 locus. Figure 5.4 A schematically depicts features of the targeting
vector as well as the applied targeting strategy. Locus specific recombination in targeted
embryonic stem cells was assessed by southernblot analysis. Size-separated XbaI -digested
genomic DNA was exposed to a 5′-located probe, resulting in the detection of a 4.6kb
fragment for the WT, and an 8.9kb fragment for the targeted allele. Successful targeting
of the ROSA26 locus is representatively shown for one embryonic stem cell clone (Figure
5.4 B). Altogether, 28% of all screened clones carried the targeted allele. Germline trans-
mitting chimeras were obtained from two independent clones, and breeding to C57BL/6
mice resulted in the generation of the ROSA26loxSTOP lox−ITK−SY K mouse strain. It carried
the ITK-SYK cDNA within the recombined (Rec) ROSA26 locus heterozygously. In these
mice transcriptional readthrough from the Rec locus is still interrupted by the presence of
the NEO-STOP cassette. Only upon breeding with promoter-specific Cre transgenic mice,
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the loxP site flanked NEO-STOP cassette is excised from intron 1. The splice acceptor
(SA), which is positioned upstream of the ITK-SYK sequence, hence allows correct splicing
onto the endogenous exon 1 of the ROSA26 locus and production of an exon 1-ITK-SYK-
IRES-eGFP bi-cistronic mRNA becomes possible. Since no open reading frame is defined
for an exon 1 containing transcript from the WT ROSA26 locus, translation is initiated
at the start codon provided by the ITK-SYK cDNA. The internal ribosomal entry site
enables additional translation of the eGFP protein from the bi-cistronic transcript. Green
fluorescence thus allowed detection of cells expressing the ITK-SYK cDNA and could be
used for cell tracking throughout mouse analysis.
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Figure 5.4: Successful targeting of the ROSA26 locus. (A) Schematic representation
of the gene targeting strategy. A targeting vector that carries the human ITK-SYK cDNA together with
an IRES eGFP sequence preceded by a loxP site flanked NEO-STOP cassette was constructed and used
to generate ROSA26loxSTOPlox−ITK−SY K mice as described (Subsection 4.5.2). The wildtype (WT),
recombinant (Rec) ROSA26 locus and the ITK-SYK expressing locus upon Cre mediated deletion of
the NEO-STOP cassette are indicated. Black bars highlight regions for homologous recombination in
intron 1. SA, splice acceptor site; pA, polyadenylation signal sequence; 1-3, ROSA26 exon 1-3; probe,
flanking probe for southernblot analysis. (B) Southernblot analysis. Genomic DNA from a WT and a
successfully targeted ROSA26loxSTOPlox−ITK−SY K embryonic stem cell clone was digested with XbaI
and southernblotted with the 5′-flanking probe as indicated in (A). A total number of n=42 ESCs were
screened for recombination events. Sizes of the WT and Rec fragments are indicated.
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5.2.2 Cell Type Specific Expression of ITK-SYK
The availability of the conditional ROSA26loxSTOP lox−ITK−SY K mouse strain enabled the
study of ITK-SYK in a cell type specific manner. Two parallel breeding approaches
were pursued. To generate mice expressing ITK-SYK in a T cell restricted manner,
ROSA26loxSTOP lox−ITK−SY K mice were crossed with CD4-Cre transgenic mice [108] (Fig-
ure 5.5 A). To additionally study the effects of ITK-SYK expression on B lympho-
cytes, ROSA26loxSTOP lox−ITK−SY K mice were crossed with CD19-Cre transgenic mice
[150] (Figure 5.5 B). The resulting offspring were referred to as ITK-SYKCD4−Cre and
ITK-SYKCD19−Cre mice, respectively. As outlined in Subsection 5.2.1, Cre-mediated ex-
cision of the loxP site flanked NEO-STOP cassette, is expected to permit the expression
of the fusion kinase ITK-SYK as well as the fluorescent protein eGFP from a bi-cistronic
mRNA. Thus, functionality of the resulting mouse strains was tested by flow cytometry
and westernblot analysis of splenocytes isolated from 5 week old ITK-SYKCD4−Cre and
ITK-SYKCD19−Cre mice. Flow cytometric analysis in both strains showed that over 80%
of T cells isolated from ITK-SYKCD4−Cre mice or B cells isolated from ITK-SYKCD19−Cre
mice have functionally deleted the NEO-STOP cassette from the recombined ROSA26
allele, as determined by eGFP positivity (Figure 5.6 A). Westernblot analysis with an
ITK specific antibody further confirmed cell type specific expression of the fusion ki-
nase ITK-SYK from the respective mouse strain (Figure 5.6 B). ITK-SYK was detected
at a size of 54kDa, as expected. Since only one targeted ROSA26 allele is present in
Figure 5.5: Breeding scheme. (A) ROSA26loxSTOPlox−ITK−SY K mice were crossed with
CD4-Cre transgenic mice for T cell specific expression of ITK-SYK, generating the ITK-SYKCD4−Cre
strain. (B) For B cell specific expression ROSA26loxSTOPlox−ITK−SY K mice were crossed to CD19-Cre
transgenic mice, resulting in the ITK-SYKCD19−Cre strain. For both breeding approaches eGFP ex-
pression indicates successful Cre-mediated deletion of the loxP site flanked NEO-STOP cassette and
expression of the ITK-SYK cDNA.
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Figure 5.6: Conditional Expression of ITK-SYK in T or B cells in vivo. (A)
ROSA26loxSTOPlox−ITK−SY K mice were crossed to CD4-Cre or CD19-Cre transgenic mice for T cell
or B cell specific ITK-SYK expression, respectively. Peripheral lymphocyte suspensions from spleens of
5 week old ITK-SYKCD4−Cre, or ITK-SYKCD19−Cre mice were stained against TCRβ or B220. eGFP
fluorescence indicative of ITK-SYK expression in the TCRβ+ T cells or B220+ B cells of the respec-
tive animals was analyzed using flow cytometry. Data shown are representative of over forty mice per
genotype analyzed. (B) Mature T or B cell populations from 5 week old ROSA26loxSTOPlox−ITK−SY K ,
ITK-SYKCD4−Cre or ITK-SYKCD19−Cre mice were sorted with magnetic beads and subjected to west-
ernblot analysis with an α-ITK antibody. Bands of wildtype ITK (72kDa) and recombinant ITK-SYK
(54kDa) are indicated. Westernblotting for β-actin (42kDa) demonstrated equal protein loading. Data
shown are representative of five independent experiments.
both mouse strains - resulting from a heterozygous breeding approach - ITK-SYK was
expressed to a lesser extent than seen for the T cell specific endogenous ITK protein.
Favorably for later strain comparison, both T cells isolated from ITK-SYKCD4−Cre and
B cells isolated from ITK-SYKCD19−Cre mice showed equal expression levels of the fu-
sion kinase (Figure 5.6 B). These initial results confirm the functionality of the generated
ROSA26loxSTOP lox−ITK−SY K mouse strain.
5.2.3 ITK-SYK Can Imitate a TCR Signal In Vivo
Since the ITK-SYK producing translocation has been originally isolated from patients
diagnosed with PTCL-NOS, the primary focus was on investigating ITK-SYK related
effects on T cell development and activation. Those aspects were first analyzed by flow
cytometry in 4-5 week old ITK-SYKCD4−Cre mice. Within these mice the Cre recombi-
nase expression is put under the control of the CD4 promoter. Therefore, excision of the
NEO-STOP cassette and subsequent ITK-SYK expression was expected to begin at the
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double positive (DP) CD4+CD8+ thymocyte stage and to continue throughout the CD4+
T cell lineage [108]. In agreement with that, recombination of the NEO-STOP cassette,
as indicated by eGFP fluorescence, was detected within the DP thymocyte compartment
in ITK-SYKCD4−Cre mice. Full fluorescence levels were reached within the further ma-
tured CD4+ or CD8+ single positive (SP) population (Figure 5.7 A). Over 90% of the SP
CD4+ and 75% of the SP CD8+ cells were eGFP+, indicative of ITK-SYK expression.
Concerning thymic development, ITK-SYK expression resulted in a striking reduction of
DP thymocytes as seen by a decrease in both frequency and total cell number (Figure 5.7
B, C). The amount of CD4+ SP and CD8+ SP thymocytes was also severely diminished
(Figure 5.7 C). Regarding peripheral lymphoid populations, a profound loss of mature
T cells in lymph node and spleen was observed, as shown by both a reduction in fre-
quency (Figure 5.8 A) and a reduction of total cell numbers (Figure 5.8 B). Amongst
the T cells, both CD4+ and CD8+ cells were equally affected as is shown by diminished
frequencies in lymph node and spleen (Figure 5.8 C). Total B cell numbers, however,
remained unaltered in ITK-SYKCD4−Cre mice (Figure 5.8 B).
Flow cytometric analysis further revealed that the majority of mature T cells present
in the periphery expressed ITK-SYK, as detected by eGFP expression (Figure 5.6 A, Fig-
ure 5.8 D). They also displayed an activated phenotype as indicated by a cell size increase,
high expression of the activation marker CD44 [41], and low expression of the naive T cell
marker CD62L [170] (Figure 5.9 A). This pattern was accompanied by a reduced sur-
face expression of the TCRβ chain, being an additional characteristic of activated T cells
[189]. The described phenotype was seen for both the CD4+ and the CD8+ T cell pop-
ulation. Loss of CD62L was observed to a lesser extent for CD8+ T cells compared to
the CD4+ T cell population (Figure 5.9 A). Being in line with an activated phenotype
and previously performed in vitro experiments (Figure 5.2 A), peripheral T cells isolated
from ITK-SYKCD4−Cre mice showed constitutive lipid raft recruitment of the TCR sig-
nal transducer p-PLCγ1 (Figure 5.9 B). The degree of phosphorylation was similar to
wildtype T cells isolated from CD4-Cre control mice stimulated via α-CD3e and α-CD28
antibodies (Figure 5.9 B).
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Figure 5.7: ITK-SYK induces loss of thymocytes in ITK-SYKCD4−Cre mice. (A)
Thymocytes were stained against CD4 and CD8, and analyzed by flow cytometry. eGFP fluorescence
indicative of ITK-SYK expression was measured in the CD4+/CD8+ double positive (DP) and in the
CD4+ or CD8+ single positive (SP) populations of 4-5 week old ITK-SYKCD4−Cre and CD4-Cre control
mice. (B and C) ITK-SYK induces DP thymocyte deletion. (B) Thymocytes were stained as in (A)
and analyzed for the expression of CD4 or CD8. The frequencies of individual thymocyte subsets are
indicated. Data shown in (A) and (B) are representative of five independent experiments with at least
ten mice analyzed per genotype. (C) The total DP, CD4 SP, or CD8 SP thymocyte cell numbers from
ITK-SYKCD4−Cre (n=9) or CD4-Cre control (n=6) mice are shown. Each symbol represents an individual
mouse. Statistical significance was analyzed using the unpaired two-tailed Student’s t test. Statistically
significant (***p<0.0001; **p=0.0027). Horizontal bars indicate the means.
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Figure 5.8: ITK-SYK induces loss of peripheral T cells in ITK-SYKCD4−Cre
mice. (A, C) Single cell suspensions from lymph nodes (LN) or spleens (SPL) from 4-5 week old
ITK-SYKCD4−Cre or CD4-Cre control mice were either stained against TCRβ and B220 (A) or CD4
and CD8 (C), and analyzed by flow cytometry. The frequencies of individual TCRβ+, B220+, CD4+,
and CD8+ subsets in LN and SPL are indicated. (B) Total splenic B cell or T cell numbers from
ITK-SYKCD4−Cre (n=10) or CD4-Cre control (n=9) mice are indicated. Each symbol in (B) repre-
sents an individual mouse. D) eGFP fluorescence indicative of ITK-SYK expression was determined in
peripheral CD4+ or CD8+ T cells of ITK-SYKCD4−Cre and CD4-Cre control mice. Data from spleen are
shown. Statistical significance was analyzed using the unpaired two-tailed Student’s t test. ***, statisti-
cally significant (p<0.0001); ns, not statistically significant (p≥0.05). Horizontal bars indicate the means.
Data shown in (A), (C) and (D) are representative of five independent experiments with at least ten mice
analyzed per genotype.
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Figure 5.9: ITK-SYK expressing T cells exhibit an activated phenotype in
vivo. (A) Peripheral lymphocytes from 4-5 week old ITK-SYKCD4−Cre or CD4-Cre control mice were
stained against CD4, CD8, CD44, CD62L, and TCRβ. Forward scattering (FCS) as a parameter for
cell size and expression of CD44, CD62L, and TCRβ were analyzed in the CD4+ and CD8+ T cell
compartment using flow cytometry. Data shown are representative of five independent experiments with
at least ten mice analyzed per genotype. (B) ITK-SYK induces PLCγ1 phosphorylation in primary T cells
in vivo. Splenic T cells were isolated from CD4-Cre control or ITK-SYKCD4−Cre mice that were over
12 weeks old. Cells were left unstimulated and control cells were additionally stimulated with 5µg/ml of
α-CD3e and 1µg/ml of α-CD28. Lipid raft fractions were prepared and subjected to westernblot analysis
with an antibody directed against p-PLCγ1. Dot blots for GM1 show successful raft preparation and
equal protein loading. Data are representative of three independent experiments. Black lines indicate
that intervening lanes have been spliced out.
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Figure 5.10: ITK-SYK expressing T cells proliferate but do not undergo
apoptosis in vivo. Spleen sections of 4-5 week old ITK-SYKCD4−Cre or CD4-Cre control mice
were used for immunohistochemistry with antibodies directed against CD3, Ki-67, or the cleaved active
form of caspase 3 (caspase 3A). Data are representative of three ITK-SYKCD4−Cre and two CD4-Cre
control mice analyzed. Bars, 1.2mm.
To further characterize the activated T cells and to address the possible effect of
ITK-SYK expression on T cell proliferation and survival, immunohistochemical anal-
yses were performed on spleen sections from ITK-SYKCD4−Cre and CD4-Cre control
mice. Diffusely distributed CD3+ T cells showed strong proliferative features as deter-
mined by staining against the proliferation marker Ki-67 [164] in comparison to control
spleen samples (Figure 5.10). However, no increased apoptosis was detectable in spleens
from ITK-SYKCD4−Cre mice when stained against the apoptotic marker molecule active
caspase-3 [140].
Concludingly, data demonstrate that a T cell specific expression of ITK-SYK leads to
a severe loss of thymic T cells in ITK-SYKCD4−Cre mice. Although strongly reduced in cell
numbers, matured T cells emerging from the thymus are activated and in a proliferative
state. These observations substantiate the postulation made from in vitro experiments
that ITK-SYK mimics aspects of a strong TCR signal.
5.2.4 ITK-SYK Does Not Affect BCR Signaling In Vivo
Due to the fact that SYK is an essential receptor proximal tyrosine kinase initiating
BCR signaling [102], it was of additional interest to study the potential effect of the
fusion kinase ITK-SYK on B cell development and activation. For that purpose, the pre-
viously mentioned ITK-SYKCD19−Cre mouse strain (Subsection 5.2.2) was analyzed at
5-7 weeks of age. Since within these mice Cre recombinase expression relies on CD19
promoter activity, deletion of the NEO-STOP cassette and consequent ITK-SYK expres-
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sion was expected to begin in early B cell compartments and to continue throughout
B cell development and maturation [161]. In consistency with that, successful recombi-
nation, as indicated by eGFP expression, was first detected in a low percentage B cells
within the bone marrow (BM). However, peripheral splenic B cell compartments, such as
follicular (FO) and marginal zone (MZ) B cells, and peritoneal B1 B cells showed high
recombination frequencies of over 80% (Figure 5.11 A, Figure 5.6 A). Surprisingly, flow
cytometric analysis revealed that ITK-SYK expression had no effect on B cell develop-
ment in the bone marrow, as seen by normal distributions of pro/pre (B220lowIgMneg),
immature/transitional (B220low−hiIgMint−hi), and mature/recirculating (B220hiIgMint) B
cells in ITK-SYKCD19−Cre compared to CD19-Cre control mice (Figure 5.11 B). Similarly,
no significant deviations were observed among the frequencies of peripheral splenic B cells
from ITK-SYKCD19−Cre mice (Figure 5.11 C). These included follicular (CD21intCD23hi),
non-follicular (CD21lowCD23low), and marginal zone (CD21hiCD23low) B cells (Figure 5.11
D). The same holds true for peritoneal B1 B cells (B220intCD5int) (Figure 5.11 E). Not
only B and T cell distribution but also total B and T cell numbers were unaffected as
demonstrated for the spleen of ITK-SYKCD19−Cre and CD19-Cre control mice (Figure
5.11 C, F). To further investigate possible effects of ITK-SYK on B cell physiology, the
activation status of peripheral B cells prepared from ITK-SYKCD19−Cre mice was assessed.
Neither an increase in cell size nor an upregulation of the activation marker CD86 [20]
were detected for ITK-SYK expressing B cells (Figure 5.12 A). Additionally, no difference
in the overall tyrosine phosphorylation pattern was observed in purified splenic B cells
isolated from ITK-SYKCD19−Cre in comparison to CD19-Cre control mice (Figure 5.12
B).
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Figure 5.11: B cell-intrinsic ITK-SYK expression does not affect B cell
development. (A) Single cell suspensions from the bone marrow (BM), spleen (SPL) or peritoneal
cavity of ITK-SYKCD19−Cre or CD19-Cre control mice were stained against B220, CD21, CD23, and
CD5. eGFP fluorescence indicative of ITK-SYK expression was determined in gated B220+ cells from
BM, SPL, follicular (FO), non-follicular (NF), marginal zone (MZ), or peritoneal B1 B cell compartments
using flow cytometry. (B)-(E) Lymphocyte preparations from BM (B), SPL (C,D) or peritoneal cavity
(E) of ITK-SYKCD19−Cre or CD19-Cre control mice were stained against the indicated surface markers
and analyzed by flow cytometry. The percentages of individual B cell populations are indicated. B220+
cells were gated for (B) and (D). FO, follicular B cells; MZ, marginal zone B cells. (F) Total splenic B
or T cell numbers from ITK-SYKCD19−Cre (n=12) or CD19-Cre control (n=6) mice are shown. Each
symbol represents an individual mouse. Statistical significance was analyzed using the unpaired two-tailed
Student’s t test. ns, not statistically significant differences (p≥0.05). Horizontal bars indicate the means.
Data shown in (A)-(E) are representative of four independent experiments with at least six 5-7 week old
mice analyzed per genotype.
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In vitro experiments performed in JurkatE T cells showed that PH domain-mediated
membrane recruitment of ITK-SYK was necessary for ITK-SYK functionality (Figure 5.2
A, Figure 5.3 A, B). To analyze whether the observed differences in the T and B cell
phenotype might be due to differences in ITK-SYK positioning at the cell membrane,
lipid raft experiments were performed. Purified T cells from ITK-SYKCD4−Cre and pu-
rified B cells prepared form ITK-SYKCD19−Cre mice were subjected to westernblotting
with an ITK-specific antibody. T cells purified from ROSA26loxSTOP lox−ITK−SY K mice
were used as a control. Experiments demonstrated that both ITK-SYK and endogenous
ITK molecule were strongly recruited into the lipid rafts of T cells, a feature already
observed in retrovirally infected JurkatE T cells expressing ITK-SYK (Figure 5.2 A).
However, ITK-SYK could not be detected in the lipid raft fraction of B cells isolated from
ITK-SYKCD19−Cre mice, although the fusion kinase was expressed in both T and B cells to
similar amounts as seen for the non-raft fractions (Figure 5.12 C). Equal protein expres-
sion was also previously shown for splenic cytosolic lysates from both ITK-SYKCD4−Cre
and ITK-SYKCD19−Cre mouse strains (Figure 5.6 B).
All in all, the analysis of ITK-SYKCD19−Cre mice showed that neither B cell devel-
opment and maturation nor B cell activation were affected by a B cell specific expression
of ITK-SYK. The missing membrane recruitment of ITK-SYK to the antigen receptor
environment may be held accountable for the surprising differences being seen in the ef-
fect the fusion kinase has on T cells but not on B cells, despite strong similarities given
between the TCR and BCR signal initiation and transduction mechanism [90].
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Figure 5.12: Lacking B cell activation and T cell specific recruitment of
ITK-SYK into lipid rafts. (A) Forward scattering (FSC) and CD86 expression were ana-
lyzed on B220+ splenic B cells from ITK-SYKCD19−Cre or CD19-Cre control mice by applying flow
cytometry. Data shown are representative of four independent experiments with at least six 5-7 week
old mice analyzed per genotype. (B) Cytoplasmic extracts of purified splenic B cells from 5 week
old ITK-SYKCD19−Cre or CD19-Cre control mice were subjected to westernblot analysis with an
antibody directed against ITK and total phospho-tyrosine residues (p-Tyr). Westernblotting against
β-actin demonstrated equal protein loading. Data shown are representative of three independently per-
formed experiments. (C) Lipid raft and non-raft fractions were prepared from purified splenic T cells
of ITK-SYKCD4−Cre or ROSA26loxSTOPlox−ITK−SY K control mice or from purified splenic B cells of
ITK-SYKCD19−Cre mice that were >12 weeks of age. The fractions were subsequently analyzed for the
presence of ITK or ITK-SYK by westernblot analysis with an ITK specific antibody. Dot blots for GM1
depict successful raft preparation and equal protein loading. Data shown are representative of three
independent experiments.
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5.3 Peripheral T Cell Lymphoma in ITK-SYK
Expressing Mice
5.3.1 ITK-SYK Expression in T Cells Results in a Fatal
Lymphoproliferative Disease with Neoplastic Character
Analysis of 4-6 week old ITK-SYKCD4−Cre mice demonstrated that T cell development
and activation are affected upon T cell specific expression of the fusion kinase ITK-SYK
(Subsection 5.2.3). Thymocytes were lost at the DP and SP stage. Also, a severe loss of
T cells in the peripheral lymphoid organs was observed. The remaining peripheral T cells
however expressed ITK-SYK and displayed an activated phenotype with proliferative
features.
To see whether continued ITK-SYK expression can be accounted for lymphoma de-
velopment, longterm observations of a defined cohort of ITK-SYKCD4−Cre (n=19) and
ITK-SYKCD19−Cre (n=8) mice were initiated. Regular blood sampling was performed to
monitor the percentages of eGFP+ T cells as well as eGFP+ B cells of the respective
mouse strain via flow cytometry. As seen in Figure 5.13 A, the frequency of eGFP+
T cells increased steadily in ITK-SYKCD4−Cre up to 90%, whereas the mean frequency of
eGFP+ B cells remained fairly stable in ITK-SYKCD19−Cre animals at around 40%. Most
distinctly, during the course of observation, mice of the ITK-SYKCD4−Cre genotype were
lost by death or eventually had to be sacrificed due to increasing disease symptoms with
an onset at about 12 weeks of age. The final disease stage was characterized by wasting
and runting symptoms, lethargy, hunched postures, and distended abdomens. None of the
ITK-SYKCD19−Cre mice, however, developed disease related symptoms within that time
frame. Therefore, data obtained from blood sampling hinted towards the development of
a lymphoproliferative disorder upon T cell specific expression of ITK-SYK with a fatal
outcome for ITK-SYKCD4−Cre mice.
In order to substantiate these initial observations, survival curves from a larger
cohort of ITK-SYKCD4−Cre and CD4-Cre control mice were generated. Indeed, all
ITK-SYKCD4−Cre mice eventually succumbed to disease related symptoms within 27
weeks showing a median survival of 20.6 weeks of age (Figure 5.13 B). CD4-Cre control
mice remained unaffected. Analysis of diseased ITK-SYKCD4−Cre mice revealed enlarged
spleens with a mean 4.6 fold weight increase compared to spleens isolated from control
mice (Figure 5.13 C). Flow cytometric analysis confirmed expansion of eGFP+ T cells,
completely replacing the remaining cell compartments (Figure 5.13 D).
Further characterization followed to determine whether the lymphoproliferative dis-
ease exhibited features of a neoplastic disorder. Thus, histological analysis in combination
with studies concerning T cell clonality and transplantability were performed. As for the
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histological analysis of diseased ITK-SYKCD4−Cre mice, a complete disruption of the nor-
mal spleen architecture by a diffuse infiltrate of medium to large-sized lymphoid cells was
observed. T cells demonstrated irregular nuclei, prominent nucleoli and high mitotic rates,
all features strongly supporting a situation of neoplastic cell growth (Figure 5.14 A). The
proliferative nature of the T cells was verified by Ki-67 positivity. Flow cytometric analy-
sis showed, that in 61% of all cases the CD4+ T cell population (Type 1) was expanded,
in 23% of all cases the CD8+ T cell population (Type 2), and in 16% of all cases both
the CD4+ and the CD8+ population were expanded (Type 3). The three disease subtypes
observed in the spleens of ITK-SYKCD4−Cre mice are depicted in Figure 5.14 B. Notably,
the presence of abnormally expanding T cells was not limited to the spleen. Massive T cell
infiltration into the bone marrow (Figure 5.14 C) and into solid organs such as KID, LIV
and LNG were observed (Figure 5.14 D). T cells invading and partially destroying the
walls of blood vessels or epithelial cells were regularly detected throughout organ samples.
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Figure 5.13: Conditional expression of ITK-SYK in T cells induces a fatal
lymphoproliferative disease. (A) Peripheral blood samples from ITK-SYKCD4−Cre (starting
with n=19) and ITK-SYKCD19−Cre mice (n=8) were obtained at the indicated time points. The fre-
quencies of eGFP+ lymphocytes in individual animals were determined by flow cytometry. The total
number of ITK-SYKCD4−Cre mice declined over time as a result of disease related mortality. Horizon-
tal bars indicate the means. (B) Kaplan-Meier curve of ITK-SYKCD4−Cre (n=73) and CD4-Cre control
mice (n=15). (C) Macroscopic appearance of representative spleens from 20 week old ITK-SYKCD4−Cre
and CD4-Cre control mice are shown (in centimeters). Spleen weights from diseased ITK-SYKCD4−Cre
(n=11) and CD4-Cre control (n=6) mice are presented with mean values ±SD. Statistical significance
was analyzed using the unpaired two-tailed Student’s t test, statistically significant (***p<0.0001). (D)
Splenocytes from 20 week old ITK-SYKCD4−Cre and CD4-Cre control mice were stained with antibodies
directed against TCRβ and B220. Frequencies of the individual populations are indicated. Data shown
are representative of at least twenty mice analyzed per genotype.
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Figure 5.14: Severe organ infiltration caused by abnormal T cell expan-
sion in ITK-SYKCD4−Cre mice. (A) Disruption of the splenic architecture with highly pro-
liferative cells in ITK-SYKCD4−Cre mice was revealed by hematoxylin and eosin (H&E) staining
and immunohistochemistry with anti-Ki-67 antibodies. Bars: black, 1mm; white, 50µm. Data shown
are representative of five diseased ITK-SYKCD4−Cre mice analyzed. (B) Splenic cells from diseased
ITK-SYKCD4−Cremice were stained against CD4 and CD8 and analyzed by flow cytometry. Representa-
tive examples of T cell expansion from forty analyzed mice are shown. (C) Bone marrow cell preparations
from diseased ITK-SYKCD4−Cre or CD4-Cre control mice were stained with antibodies against TCRβ.
The frequency of eGFP+ T cells in diseased mice is indicated. Data are representative of five indepen-
dent experiments with fifteen mice analyzed per genotype. (D) Solid organ infiltration of abnormal CD3+
T cells. Tissue sections from kidney (KID), liver (LIV), and lung (LNG) of affected ITK-SYKCD4−Cre
mice were stained with H&E. Anti-CD3 antibodies were used for immunohistochemical analysis. Bars:
black, 200µm; white, 1mm. Data shown are representative of five diseased ITK-SYKCD4−Cre and three
control mice analyzed. Control mice were of CD4-Cre or ROSA26loxSTOPlox−ITK−SY K genotype. Data
in (A)-(D) are from ITK-SYKCD4−Cre mice that were older than 12 weeks of age and displayed severe
disease symptoms.
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To investigate whether the expanded T cells were of clonal origin, splenocytes iso-
lated from diseased ITK-SYKCD4−Cre and CD4-Cre control mice were stained against a
defined panel of TCRVβ chains (Subsection 3.2.3). Flow cytometric analysis revealed that
the T cell compartment of ITK-SYKCD4−Cre mice always showed an irregular distribu-
tion of individual T cell clones compared to control mice (Figure 5.15 A). Several TCRVβ
chain variants were underrepresented or lost completely, whereas the percentage of one
or few variants was increased (Figure 5.15 B). A preferential TCRVβ chain rearrange-
ment in diseased ITK-SYKCD4−Cre mice was not observed. Notably, the expanded splenic
TCRVβ-chain+ T cells were again detected in other affected solid organs such as KID
and LIV of the same diseased animal (Figure 5.15 C), indicating clonal cell expansion.
To confirm clonality on the genomic level, genescan analysis was performed to amplify
V-D-J joining regions within the rearranged TCRβ and TCRγ locus. Analyses were per-
formed in diseased ITK-SYKCD4−Cre and CD4-Cre control mice. Whereas all control T
cell samples gave rise to a plethora of PCR products with a normal size distribution, the
amplified PCR product profile from splenocytes isolated from diseased ITK-SYKCD4−Cre
mice showed that few distinct amplification products came up. Exemplary, genescan anal-
ysis for the rearrangement of the Dβ2/Jβ2 junction in T cells of a control and diseased
ITK-SYKCD4−Cre mouse are shown (Figure 5.15 D).Therefore, both flow cytometry and
genescan analysis demonstrated a clonal expansion of ITK-SYK expressing T cells in
diseased ITK-SYKCD4−Cre mice.
As a final approach to analyze the neoplastic nature of ITK-SYK expressing T
cells, transplantation experiments were performed. To this end, total splenocytes iso-
lated from ITK-SYKCD4−Cre mice were injected into the tail vein of immunocompromised
Hsd:Athymic Nude-Foxn1nu mice. The frequencies of eGFP+ cells from blood samples
were monitored over time as was the health status of the transplanted recipient mice.
Flow cytometric analysis showed that the frequency of transferred eGFP+ cells increased
steadily over time within individual recipients (Figure 5.16 A). Cells isolated from 90%
of donor mice transplanted the disease. All successfully transplanted recipients eventually
succumbed to disease symptoms such as weight loss, extended abdomen and hunched
postures with a median survival of 15 weeks post transplantation. Organ preparations re-
vealed splenomegaly (Figure 5.16 B) and flow cytometric analysis demonstrated a massive
T cell expansion within the SPL and BM of these animals (Figure 5.16 C). H&E staining
in combination with immunohistochemical detection of Ki-67 confirmed that recipient
spleens were flooded by enlarged, proliferating cells. Cell infiltration into solid organs was
further detected as exemplary depicted for LIV and LNG sections (Figure 5.16 D). The
T cell nature of the infiltrates was verified by immunohistochemical staining against the
surface marker CD3.
Ultimately, analysis of diseased ITK-SYKCD4−Cre mice showed that T cell specific
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expression of the fusion kinase ITK-SYK leads to uncontrolled T cell expansion with a fatal
outcome. The malignant phenotype of the disease was characterized by abnormal T cell
morphology and clonal expansion of highly infiltrative T cells, which upon transplantation
recreated the disease in recipient mice.
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Figure 5.15: Selective expansion of distinct T cell clones in affected
ITK-SYKCD4−Cre mice. (A) Splenocytes isolated from a CD4-Cre control and diseased
ITK-SYKCD4−Cre mouse were stained with antibodies directed against CD4, CD8, and a panel of TCRVβ
chain specific antibodies. The distribution of TCRVβ chain+CD4+ T cells is shown by histogram overlay.
(B) Splenocytes were stained as in (A). Frequencies of expanded CD4+ cells expressing the indicated
TCRVβ chains in the spleen of five diseased ITK-SYKCD4−Cre mice (#1-5, tinted histograms) are de-
picted. Control mice (untinted histograms) were of CD4-Cre or ROSA26loxSTOPlox−ITK−SY K genotype.
A total amount of n=33 diseased ITK-SYKCD4−Cre mice was screened for skewed TCRVβ chain expres-
sion. (C) Single cell suspensions from spleen (SPL), kidney (KID), and liver (LIV) of three individual mice
were stained as in (A). Frequencies of CD4+ or CD8+ cells expressing the indicated TCRVβ chains in
SPL, KID and LIV of CD4-Cre control (untinted histograms) or diseased ITK-SYKCD4−Cre mice (#6-8,
tinted histograms) are depicted. (D) Genescan analysis for TCR gene rearrangements. Representative
fragment size distributions of fluorochrome-labeled PCR products of the Dβ2/Jβ2 junction of a CD4-Cre
control and a diseased ITK-SYKCD4−Cre mouse are presented. Data shown are representative of three
mice analyzed per genotype. Data in (A)-(D) are from ITK-SYKCD4−Cre mice that were older than 12
weeks of age and showed severe disease symptoms.
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Figure 5.16: Proliferation and infiltration of ITK-SYK expressing T cells upon
transplantation. (A) Splenic cells from diseased ITK-SYKCD4−Cre mice were intravenously injected
into Hsd:Athymic Nude-Foxn1nu recipient mice for transplantation. The frequencies of eGFP+ peripheral
blood cells in the recipients were monitored over time by flow cytometry. Recipients that succumbed to
the disease are indicated (†). Representative examples are shown. Nine out of ten donor mice transplanted
the disease. Five independent transplantations were performed. (B) Spleens (SPL) from a Hsd:Athymic
Nude-Foxn1nu control and a representative recipient mouse from (A) are shown (in centimeter). (C)
Recipients were sacrificed upon signs of disease, and bone marrow (BM) and SPL suspensions were
stained against TCRβ. Representative frequencies of eGFP+ T cells in SPL and BM of ten diseased
recipients are indicated. (D) Tissue sections from SPL, liver (LIV), and lung (LNG) were analyzed by
H&E staining or by immunohistochemistry with α-CD3 or α-Ki-67 specific antibodies. Bars: black, 1mm;
white, 125µm. Representative examples of four diseased recipients are shown.
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5.3.2 Sporadic ITK-SYK Expression in Single T Cells is Able
to Induce T Cell Lymphomas in ITK-SYKCD19−Cre mice
As described in Subsection 5.2.4, B cell specific expression of the fusion kinase ITK-SYK
neither affected B cell development nor activation. Furthermore, ITK-SYKCD19−Cre
mice displayed a normal survival pattern up to 35 weeks of age. However, continued
flow cytometric monitoring of the percentage of eGFP+ cells in peripheral blood from
ITK-SYKCD19−Cre mice revealed an expanding eGFP+ population which was positive for
the T cell marker TCRβ (Figure 5.17 A). This eGFP+ T cell population had developed
next to the expected eGFP+ B cell population. With increasing percentages of eGFP+ T
cells in the peripheral blood, ITK-SYKCD19−Cre mice became overtly ill, and eventually
all mice died or had to be sacrificed for ethical reasons. ITK-SYKCD19−Cre mice displayed
a median survival of 47.4 weeks of age (Figure 5.17 B). Notably, disease symptoms were
reminiscent of ITK-SYKCD4−Cre mice and were composed of wasting and runting symp-
toms, lethargy, hunched postures, as well as extended abdomens. Extensive splenomegaly
was observed upon mouse dissection with a mean 8.3 fold weight increase compared to
CD19-Cre control mice (Figure 5.17 C). Flow cytometric analysis confirmed that the
expanded splenic eGFP+ population was of T cell origin, as shown by staining against
TCRβ (Figure 5.17 D). H&E staining in combination with immunohistochemical detec-
tion of CD3 and B220 further supported a loss of the normal splenic organization with
expansion of irregular T cells and replacement of the B cell compartment (Figure 5.17 E).
T cells were activated as determined by upregulation of CD44 and loss of the naive T cell
maker CD62L (Figure 5.18 A). Further characterization revealed that the expanding T
cell population consisted of CD4+ T cells in 75% of all diseased ITK-SYKCD19−Cre mice
(Type I). The remaining cases showed an expansion of the CD8+ T cell population (Type
II) (Figure 5.18 B). Notably, no simultaneous expansion of both the CD4+ and the CD8+
T cell population was observed. Besides uncontrolled T cell growth within the SPL, T cells
again invaded several other organs such as BM (Figure 5.18 C), LIV and LNG (Figure
5.18 D) as demonstrated by H&E staining and immunohistochemical detection of CD3.
Staining against Ki-67 verified the proliferative nature of the infiltrating T cells (Figure
5.18 D).
To define whether the observed lymphoproliferative disease holds characteristics of
a neoplastic disorder, T cell clonality was assessed in affected ITK-SYKCD19−Cre mice.
Flow cytometric analysis revealed a selective expansion of distinct TCRVβ+ T cell clones
in diseased ITK-SYKCD19−Cre compared to CD19-Cre control mice (Figure 5.19 A). As a
sign of T cell activation, downregulation of the respective TCRVβ+ chain was detected in
the gated T cell population from ITK-SYKCD19−Cre mice (Figure 5.19 A). The indicated
clonal T cell expansion was supported on a genomic level by amplification of the TCRVβ
and TCRVγ locus via multiplex PCR. Genescan analysis showed that the expected PCR
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product length distribution of T cells isolated from CD19-Cre control mice was entirely
lost in T cells isolated from diseased ITK-SYKCD19−Cre mice (Figure 5.19 B). TCR locus
rearrangements for one or more clones were predominantly observed, confirming a clonal
T cell expansion in ITK-SYKCD19−Cre mice.
Concludingly, data show that ITK-SYKCD19−Cre mice all eventually developed a
neoplastic disease of T cell origin. Although the onset was significantly delayed, the disease
phenotype was reminiscent of ITK-SYKCD4−Cre mice. Thus, results imply a scenario where
the unlikely event of CD19 promoter activity in a small number of T cells is sufficient
to induce Cre-mediated deletion of the loxP site flanked NEO-STOP cassette. Sporadic
ITK-SYK expression triggers T cell expansion and eventually leads to the development
of PTCL also in ITK-SYKCD19−Cre mice.
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Figure 5.17: ITK-SYKCD19−Cre mice develop a lymphoproliferative disease. (A)
Peripheral blood from a 25 week old ITK-SYKCD19−Cre mouse was stained against B220 and TCRβ. The
eGFP+TCRβ+ or eGFP+B220+ population is indicated. (B) Kaplan-Meier curve of ITK-SYKCD19−Cre
(n=18) and CD19-Cre control mice (n=10). (C) Splenomegaly in ITK-SYKCD19−Cre mice. Represen-
tative spleens from 50 week old CD19-Cre control and diseased ITK-SYKCD19−Cre mice are shown (in
centimeter). Spleen (SPL) weights from diseased ITK-SYKCD19−Cre (n=15) and CD19-Cre control mice
(n=8) are depicted with mean values±SD. Statistical significance was analyzed using the unpaired two
tailed Student’s t test, statistically significant (***p<0.0001). (D) Splenocytes from 50 week old CD19-Cre
control and ITK-SYKCD19−Cre mice were stained against TCRβ. The frequency of eGFP+ T cells in
a representative ITK-SYKCD19−Cre mouse is indicated. Data in (A), (C), and (D) are representative
of six independent experiments with at least eight mice analyzed per genotype. (E) H&E staining and
immunohistochemistry with α-CD3 and α-B220 antibodies were performed on SPL sections. Bars: black,
500µm; white, 125µm. Data representative of six diseased ITK-SYKCD19−Cre mice are shown.
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Figure 5.18: ITK-SYKCD19−Cre mice display organ infiltration by activated T
cells. (A) Expanded T cells in ITK-SYKCD19−Cre mice display an activated phenotype. Splenocytes
of 50 week old CD19-Cre control (untinted histograms) and diseased ITK-SYKCD19−Cre mice (tinted
histograms) were stained against CD4, CD44 and CD62L. Surface expression of CD44 and CD62L were
assessed by flow cytometry from gated CD4+ T cells. (B) Splenocytes from diseased ITK-SYKCD19−Cre
mice (n=16) were stained against CD4 and CD8. Examples of preferential CD4+ T cell (Type I) or CD8+
T cell (Type II) expansions are shown. (C) Bone marrow cell suspensions of 50 week old CD19-Cre control
and diseased ITK-SYKCD19−Cre mice were stained against TCRβ. The frequency of eGFP+ T cells
in a representative diseased ITK-SYKCD19−Cre mouse is indicated. (D) Solid organ infiltration with
abnormally proliferating T cells in ITK-SYKCD19−Cre mice. H&E staining and immunohistochemistry
with anti-CD3 and anti-Ki-67 antibodies were performed on liver (LIV) and lung (LNG) sections. Bars,
1mm. Data representative of six diseased ITK-SYKCD19−Cre mice are shown. Data in (A) and (C) are
representative of six independent experiments with at least ten mice analyzed per genotype.
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Figure 5.19: Selective expansion of distinct T cell clones in ITK-SYKCD19−Cre
mice. (A) Single cell suspensions from spleens of CD19-Cre control (untinted histograms) and diseased
ITK-SYKCD19−Cre mice (tinted histograms) were stained with antibodies directed against CD4, CD8,
and a panel of TCRVβ chain specific antibodies (Subsection 3.2.3). Frequencies of expanded CD4+ or
CD8+ T cells expressing the indicated TCR-Vβ chains from individual, diseased ITK-SYKCD19−Cre mice
(#1–6) are shown. A total number of n=12 diseased ITK-SYKCD19−Cre mice was screened for skewed
TCRVβ chain expression. (B) Genescan analysis for TCR gene rearrangements. Representative fragment
size distributions of fluorochrome labeled PCR products of the Dβ2/Jβ2 junction of a CD19-Cre control
mouse and a diseased ITK-SYKCD19−Cre mouse are depicted. Data shown are representative of five mice
analyzed per genotype.
Chapter 6
Discussion
6.1 ITK-SYK: Investigating a Novel Fusion Protein
Aiming at understanding deregulated signaling pathways and their role in tumorigenic
processes, a novel gene fusion found in a subgroup of patients diagnosed with PTCL-NOS
was recognized. The chromosomal translocation t(5;9)(q22;q33) involves the ITK and SYK
gene locus and leads to the production of an unprecedented fusion transcript, encoding
for the tyrosine kinase ITK-SYK [178]. Despite its novelty, interest in the translocation
was additionally given since it involved two kinases, which both are key players in AgR
signaling [90].
Especially in the field of hematological disorders, it is well established that the iden-
tification of cytogenetic aberrations is a key step in the classification and eventual molec-
ular understanding of a tumorigenic entity. Even if genomic aberrations concern merely
a small fraction of patient samples, studies have shown that gene loci hit by chromoso-
mal rearrangements are often affected by other mutations, leading to signal deregulation
[157]. Thus, chromosomal aberrations might suggest a more general mechanism in tumor
initiation, maintenance or progression. Affected molecules or downstream pathways might
therefore constitute promising and rational targets for therapeutic intervention. The de-
scribed process of identifying a translocation, understanding the molecular consequences,
and using this knowledge to develop a treatment strategy, has been successfully applied
for the tyrosine fusion kinase BCR-ABL. The fusion kinase is expressed as a result of
the reciprocal translocation t(9;22)(q34;q11), being present in 95% of all cases of chronic
myeloid leukemia (CML) [125]. The translocation was the first recurrent genetic aberra-
tion to be associated with a human cancer [156, 42], and is now a prime example for the
strategic approach to target aberrant tyrosine kinase activity by small molecule inhibitors
[205]. In the case of CML, understanding cancer pathogenesis was clearly accelerated by
the availability of mouse models [95]. In vivo systems help to validate in vitro observations,
and at present are still a reasonable choice for evaluating therapeutic approaches during
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preclinical investigations. Compiling studies within the complexity of a whole organism
becomes especially relevant when dealing with a multistep process such as tumorigenesis.
As for PTCL-NOS, no genetically reproducible in vivo models were available prior
to this work. With the knowledge on the recurrent translocation t(5;9)(q22;q33), the
aim was to describe in vitro and in vivo effects of ITK-SYK expression, and to answer
the question whether a causal link between the presence of ITK-SYK and the devel-
opment of PTCL exists. Since the question called for a cell type specific investigation,
conditional gene targeting employing the Cre/lox-P system was chosen. Implications from
both analysis in Jurkat E T cells and the generated mouse strains ITK-SYKCD4−Cre and
ITK-SYKCD19−Cre for ITK-SYK functionality and its disease correlation are outlined in
the following.
6.2 In Vitro Implications of Aberrant ITK-SYK
Signaling
Based on translocation t(5:9)(q33;q22) [178], the hypothesis was put forward that
ITK-SYK induces T cell activation and that the related cellular changes eventually lead
to T cell transformation. Initial in vitro investigations had indeed shown that ITK-SYK
expression triggers events that are characteristic of activated T cells. On a molecular
level this is reflected by recruitment of tyrosine phosphorylated proteins into lipid rafts of
ITK-SYK expressing JurkatE T cells. Accumulation of signaling proteins into lipid rafts
and raft clustering are important events in AgR signaling [168]. It is known that antigen
mediated TCR ligation induces activation of the SRC kinase LCK, which upon ITAM
phosphorylation recruits the SYK family member ZAP-70 to the receptor complex. Cor-
rectly positioned within the LAT/SLP-76 signalosome, phosphorylated PLCγ1 generates
the second messengers DAG and IP3. Both molecules eventually induce T cell activa-
tion by engaging several signaling cascades [171]. The here presented experiments showed
that phosphorylated PLCγ1 was constitutively associated with lipid rafts in ITK-SYK ex-
pressing JurkatE T cells. Next to phosphorylated PLCγ1, phosflow analysis demonstrated
activating phosphorylation of the scaffold proteins SLP-76 and LAT. Additionally, phos-
phorylation of LCK was observed (Julian Holch, medical student in the lab, unpublished
data). Thus, these data support a scenario where ITK-SYK expression results in the acti-
vation of TCR proximal signaling molecules. Furthermore, phosphorylation of AKT indi-
cated that the PI3K signaling pathway is activated, which in T cells is regularly engaged
by signaling from the costimulatory molecule CD28 [171]. Nonetheless, it has to be taken
into consideration that Jurkat T cells intrinsically show irregular PI3K activity due to
PTEN deficiency [1]. However, in all retroviral infection experiments, ITK-SYK express-
ing JurkatE T cells were compared to empty vector control JurkatE T cells. Therefore,
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increased AKT phosphorylation indicative of PI3K activity can be attributed to ITK-SYK
activity.
As distal signaling events, ITK-SYK induced activation of the MAPKs p38 and
ERK1/2. In concurrence, other authors also described activating phosphorylation of
SLP-76 [82], AKT [151], and ERK1/2 [151] in 292 T cells. Via inhibitor studies Julian
Holch showed that not only the MAPK signaling pathways but also the NFkB, the Cal-
cineurin, as well as the STAT5 signaling pathways are activated by the fusion kinase
ITK-SYK (unpublished data). Activation of STAT-5 by ITK-SYK has also been demon-
strated by Dierks et al. [48]. Inhibition of individual signaling components reduced or
completely abrogated JurkatE T cell activation, as measured by CD69 expression and
IL-2 secretion. Both CD69 surface expression and IL-2 production are early T cell ac-
tivation markers [73, 172], and both effects were seen to be strongly induced upon
ITK-SYK expression. Notably, ITK-SYK related activation events were similarly observed
in JurkatE T cells stimulated via the TCR and the costimulatory CD28 molecule. There-
fore, the results indicate that ITK-SYK acts as an intracellular mimic of a TCR signal.
However, ITK-SYK signaling is not identical to the ligand-induced TCR signal. It was
observed to differ in terms of phosphorylation kinetics and quantitative aspects like in-
duction of maximal IL-2 production or CD69 expression. Moreover, while normal TCR
signaling is self-limiting at the end of an immune response [171], ITK-SYK signaling
appears to be chronic due to its independence on external TCR stimulation.
Besides the recruitment of phosphorylated proteins, ITK-SYK itself was found to be
constitutively present in JurkatE T cell lipid rafts. Membrane recruitment could be an
important factor required for ITK-SYK activation and for the fusion kinase to gain prox-
imity to its substrates (Section 6.3). Indeed, mutational in vitro analysis showed that a
defective PH domain abrogated ITK-SYK mediated T cell activation. The same outcome
was observed for the ITK-SYKKD mutant. The importance of correct enzymatic activ-
ity was further supported by the fact that treatment of ITK-SYK expressing JurkatE T
cells with the SYK inhibitor R406 blocked T cell actviation, as was determined by lack-
ing IL-2 secretion and CD69 expression. In line with this observation, Rigby et al. [151]
demonstrated that ITK-SYK kinase activity and membrane localization are also required
for ITK-SYK mediated transformation of the NIH3T3 immortalized fibroblast cell line in
vitro. Hussain et al. [82] indirectly supported the importance of membrane recruitment by
showing that ITK-SYK activation, and subsequent SLP-76 phosphorylation is dependent
on PI3K activity. PI3K is the responsible kinase to generate PIP3, which is the ligand
for PH domain mediated membrane recruitment of ITK [8]. Thus in vitro data show that
ITK-SYK functionality depends on its enzymatic activity and on membran recruitment.
As indicated here, once correctly positioned, ITK-SYK may act on various signaling pro-
teins. The upcoming chapter will take a closer look at the structural consequences of the
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translocational event and in which manner these changes can be interpreted in regard to
ITK-SYK actions downstream of the TCR.
6.3 Structural Aspects of ITK-SYK and its Potential
Mode of Action
Considering the structural and regulatory aspects of the individual translocation partners
ITK (Subsection 1.2.3) and SYK (Subsection 1.2.4), it becomes clear that the fusion ki-
nase ITK-SYK has lost most of the regulatory elements contained in the original kinases.
The discussed model for ITK regulation postulates that the kinase is kept in an enzy-
matically inactive state through intermolecular interactions between the SH3 and SH2
domains, as well as through intramolecular interactions between the PRR and the SH3
domain [8]. Additionally, an SH2 domain located cis-prolin has been suggested to promote
ITK inactivity [120]. These protein modules are lost upon translocation along with the
intrinsic tyrosine kinase domain. Merely, the PH and TH domain of ITK are retained. As
for SYK, the translocational event preserves the tyrosine kinase domain but sheds both
the linker A connected SH2 domains and nearly half of the linker B region (Figure 1.5).
Thus, the normally performed conformational changes promoting SYK inactivation, such
as linker A/B mediated tandem SH2 domain interaction with its kinase domain (Figure
1.4), appear unrealized within the fusion kinase ITK-SYK. Hence, it is well conceivable
that merely based on its domain composition, ITK-SYK might obtain a conformationally
susceptible state, promoting its enzymatic activity without the need for greater structural
changes to occur. Along this line, mutational analyses in wildtype SYK have shown that
by partial loss of the linker A region [3] or by complete loss of the tandem SH2 domains
[155], SYK enters a state of enzymatic activity. These in vitro observations support the
scenario of a constitutively active fusion kinase due to the loss of structural regulatory
elements. The only negative regulatory option maintained within the fusion kinase orig-
inates from the residual linker B region, namely tyrosine residue Tyr183. This residue
corresponds to Tyr323 in the wildtype SYK molecule. It has been shown that upon phos-
phorylation of Tyr323, binding of CBL family members to SYK occurs, mediating SYK
ubiquitinylation, and its subsequent proteasomal degradation [118]. As to whether this
mechanism is employed for ITK-SYK negative regulation is still a matter of discussion,
however, first data from bone marrow transplantation experiments have indicated that
this might be the case [48].
One prerequisite for signal initiation downstream of the TCR and BCR is for signal-
ing molecules to obtain proximity to the receptor/coreceptor complex as well as to other
lipid raft associated signaling components. From the perspective of the full length SYK
molecule, membrane recruitment and conformational activation are achieved through tan-
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dem SH2 domain binding to dp-ITAMs, which are located in the receptor associated CD3
chains in T cells or Igα and Igβ chains in B cells [90]. As preceedingly outlined, in the case
of ITK-SYK the SH2 domains are lost. However, structurally this loss seems to be com-
pensated by retaining the ITK derived PH domain. PH domains are known to facilitate
membrane recruitment by phosphoinositide binding with different substrate specificities
for either PIP2 or PIP3 [109]. PH domains are common binding modules not only used
by the TEC family of protein tyrosine kinases but also by other signaling molecules, e.g.,
PLCγ1/2, AKT or its activating kinase PDK1 [109]. As for ITK, PH domain interaction
with PIP3 is needed for ITK activation and its function in T cells [12, 28]. ITK membrane
recruitment is abrogated in the amino acid exchange mutant ITK (R29C) by destroying
the lipid binding pocket of the PH domain [28]. As stated in Section 6.2 membrane local-
ization of the respective PH domain mutated version of ITK-SYK is abolished as are its
T cell activating capacities. These data substantiate the importance of the PH domain
and support its compensatory role for the lost SYK derived SH2 domains for ITK-SYK
membrane recruitment. Next to phosphoinositide interaction, oligomerization capacities
of the PH domain are discussed in the literature [87, 80, 142]. Considering that oligomer-
ization is a common mechanism observed for oncogenic tyrosine fusion kinases to gain
enzymatic independence [110, 124], it can be hypothesized that the PH domain not only
conveys membrane localization but also ITK-SYK oligomerization. Notably, concerning
dimerization, Kolanus et al. [94] demonstrated, that clustering of the SYK kinase domain
is able to induce its enzymatic activity to a similar degree as seen upon dp-ITAM binding.
Besides the demonstrated importance of both an intact PH and functional kinase
domain for ITK-SYK activity (Section 6.2) [151, 82], another structural aspect should
be considered when hypothesizing on how the fusion kinase might operate. On the pro-
tein level, the translocational event seems to spare key tyrosine residues within the re-
maining SYK derived linker B region. Among those are tyrosine residue Tyr183, Tyr208,
and Tyr212 in the fusion protein, corresponding to tyrosine Tyr323, Tyr348, and Tyr352
in the wildtype SYK molecule. Within SYK, these sites have been shown to be tar-
geted by autophosphorylation [63] and constitute binding sites for the classical signaling
molecules: VAV1 (Tyr348) [45], PI3K(p85) (Tyr323/352) [131], PLCγ2 (Tyr348/352) [71],
and PLCγ1 (Tyr348/352) [107]. Notably, translocation t(9;12)(q22; p12), generating the
TEL-SYK fusion kinase, affects the same breakpoint region within the SYK gene locus
as in ITK-SYK [101, 178]. Future investigations will show whether q22 might present
a genomic region prone to chromosomal breaks within the SYK gene locus. In terms of
potential interaction partners, another important tyrosine residue is retained at the far C-
terminus of ITK-SYK, Tyr490. This residue corresponds to Tyr630 in the wildtype SYK
molecule. Upon BCR stimulation and subsequent Tyr630 autophosphorylation, SYK has
been shown to interact with the B cell scaffold protein BLNK (SLP-65) [99]. This interac-
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tion stabilizes SYK in a conformationally active form [99]. Due to the structural homology
between BLNK and SLP-76 [197] it is conceivable that SLP-76 recognizes phosphorylated
Tyr490, contributing to ITK-SYK stability or supporting ITK-SYK recruitment to the
LAT/SLP-76 signalosome. Until now, no experimental proof for direct interaction between
SLP-76 or BLNK with ITK-SYK is available. However, SLP-76 is phosphorylated upon
ITK-SYK expression (Section 6.2) as is BLNK [82].
On the basis of the experimental data provided and the structural aspects outlined,
the following model of ITK-SYK mediated T cell activation is presented (Figure 6.1).
ITK-SYK molecules are recruited to the membrane by PH domain interaction with PIP3.
Relocalization from the cytoplasm to the membrane and possible oligomerization could
induce conformational changes promoting ITK-SYK activity, leading to its full activation
by autophosphorylation or phosphorylation in trans, as suggested by Rigby et al. [151].
Yet, since SYK activation in T cells can occur in a CD45 and LCK independent fashion
[34], it is conceivable that this concept also applies to ITK-SYK. SRC kinase independency
would support the observation that even without regular TCR stimulation ITK-SYK con-
veys its enzymatic activity (Section 6.2). Once phosphorylated and positioned within the
proximity of lipid raft associated kinases and scaffold proteins, ITK-SYK activity results
in phosphorylation of key signaling proteins. Since SYK derived tyrosine residues are re-
tained in the fusion kinase, direct binding to PI3K, VAV1, PLCγ1, LCK and SLP-76 seem
possible. Next to conveying protein phosphorylation, ITK-SYK might also participate in
LAT/SLP-76 signalosome stabilization, promoting signal relay. Subsequently, once acti-
vated, PLCγ1 generates the second messengers DAG and IP3, engaging Ca2+-dependent
and MAPK signaling pathways. Expression of IL-2 eventually would induce T cell pro-
liferation through autokrine stimulatory JAK/STAT signaling [152]. ITK-SYK mediated
activation of VAV1 would affect cytoskeletal reorganization, necessary for T cell activa-
tion through raft clustering and synapse formation [77]. Thus, on several levels ITK-SYK
could promote signal initiation similarly as induced upon T cell stimulation.
Following signal initiation, several factors could be involved in sustaining ITK-SYK
induced signal tranduction. One critical point might stem from ITK-SYK mediated PI3K
activation. Subsequent increased PIP3 availability would establish a positive feedback loop
for continued membrane recruitment of the fusion kinase. Besides ITK-SYK accumula-
tion, high PIP3 levels would also lead to an increased recruitment of other PH domain
carrying signaling molecules present in the T cell, such as ITK, AKT, PDK1 or PLCγ1.
Constitutive recruitment of PLCγ1 and endogenous ITK, indeed, was observed in JurkatE
T cells and as later stated (Section 6.4) also in primary cells upon ITK-SYK expression.
Thus, PI3K activation could present a key mechanism for ITK-SYK to amplify signaling
events independently from the CD28 provided costimulatory signal, regularly needed for
PI3K activation in T cells [90]. Another important factor in signal amplification might
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result from ITAM phosphorylation. In T cells it has been shown, that SYK can phos-
phorylate ITAM tyrosine residues of CD3 receptor associated chains [105, 26]. Thus, the
fusion kinase might also target ITAMs when recruited to lipid rafts and positioned within
the proximity of the TCR/CD3 receptor complex. As a consequence, SYK and ZAP70
could interact with dp-ITAMs via their tandem SH2 domains and upon activation engage
familiar signaling cascades downstream of the TCR/CD3 complex [171]. Since LCK is
phosphorylated upon ITK-SYK expression, the fusion kinase might further establish a
positive feedback loop by TCR independent LCK activation, resulting in sustained ITAM
phosphorylation.
All in all, the structural composition of ITK-SYK, its enzymatic activity together
with the opportunities for interacting with key signaling components, offers many oppor-
tunities to promote T cell activation and proliferation. In what way ITK-SYK activity
affects primary T cells and whether the fusion kinase is able to cause malignant cell growth
Figure 6.1: Model of ITK-SYK induced TCR signaling. Within this scheme, ITK-SYK
targets are depicted (arrows). It is theorized that through activation of both TCR proximal molecules
and costimulatory signaling components, ITK-SYK engages cell survival and proliferation pathways.
Autocrine IL-2 stimulation sustains cell proliferation in a TCR receptor independent manner promoting
T cell transformation. Blue arrrows indicate potential ITK-SYK targets, which still need experimental
verification. Details are given in Section 6.3.
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has been addressed by in vivo investigations as discussed in the following.
6.4 Pathological Outcome of ITK-SYK Expression
The conclusion drawn from in vitro experiments that ITK-SYK has the potential to mimic
a TCR signal, was indeed reflected in young ITK-SYKCD4−Cre mice. Depending on the
cellular context, ITK-SYK expression resulted, on the one hand, in a severe loss of DP
thymocytes, and, on the other hand, in activation of mature peripheral T cells. Deletion of
thymocytes at the DP stage is part of a naturally ocurring process, referred to as negative
selection [31]. DP thymocytes which bind MHC/self peptide complexes too strongly via
their TCR are not rescued from apoptosis, and die. Through this mechanism, potentially
autoreactive T cells are eliminated before maturation is even completed [31]. Thus, the
observation that ITK-SYK expression correlates with increased cell death at the DP stage,
strongly supports the hypothesis that ITK-SYK induces intracelluar signaling events sim-
ilar to those provided by a strong TCR stimulation. Low DP thymocyte numbers resulted
in reduced numbers of SP thymocytes as well as reduced numbers of mature peripheral
T cells. However, those cells which eventually enter the periphery, either CD4+ or CD8+
T cells, do so in an activated state. Cells are enlarged, show upregulation of the activation
marker CD44, and downregulation of the naive homing receptor CD62L. In line with an
activated status, reduced TCRβ surface expression is also observed. Immunohistological
analysis (performed in collaboration with Leticia Quintanilla-Fend) further depicted that
T cells were positive for the proliferation marker Ki-67, and no signs of increased apop-
tosis were observed. On a molecular level, T cell activation was reflected by constitutive
recruitment of phosphorylated PLCγ1 and ITK into lipid rafts, as was already observed
for JurkatE T cells. Again, CD3/CD28 stimulation of control T cells resulted in PLCγ1
recruitment to a similar extent as was seen for ITK-SYK expressing T cells. Therefore, not
only in vitro but also in vivo ITK-SYK expression induced an activated T cell phenotype.
The final question to be answered was, whether this state of T cell activation pro-
motes T cell transformation. Interestingy, gene expression profiling studies on PTCL-NOS
samples have shown that malignant cells most closely resemble mature activated CD4+
or CD8+ T cells [139]. General characterization showed that the majority of PTCL-NOS
cases are derived from CD4+ T cells [154] and strongly express the prolfieration marker
Ki-67 [163]. To investigate the outcome of ITK-SYK induced T cell activation, longterm
observations of ITK-SYKCD4−Cre mice were conducted. Although initially reduced in cell
numbers, mature T cells expanded steadily. Histological investigations confirmed their
proliferative nature by Ki-67 positivity and further demonstrated abnormal nuclear fea-
tures. Evenmore, T cells grew invasively into both lymphoid and non lymphoid areas.
All three aspects are highly indicative of a neoplastic phenotype. Clonal T cell expansion
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as well as the fact that malignant T cells could elicite a phenotypically equal disease in
recipient mice, further substantiated the neoplastic character of the lymphoproliferative
disease, allowing it to be classified as PTCL. The lymphoma showed full penetrance with
a medium latency of 20.6 weeks. In the majority of cases expanded T cell clones originated
from CD4+ T cells. Fewer cases showed outgrowth of CD8+ clones or a parallel expansion
of both cell types. Next to the pathological features, such as extranodal involvement and
the high proliferative index, the preferred clonal outgrowth of mature CD4+ tumors is
also in line with features described for human PTCL. In conclusion, ITK-SYK expression
ultimately was able to induce PTCL with 100% penetrance, resembling aspects of the hu-
man disease. Since individual T cell clones expanded in ITK-SYKCD4−Cre mice, it is likely
that cooperating events next to ITK-SYK contribute to their proliferative advantage.
Due to the fact that SYK is the main non receptor tyrosine kinase acting downstream
of the BCR, and that strong similarities between AgR proximal as well as distal signaling
events exist, it was further of interest to investigate possible effects of ITK-SYK activity on
B cells. Quite astoundingly, B cell specific expression of ITK-SYK in vivo neither affected
B cell development nor B cell activation. In vitro investigations by Dierks et al. [48] also
showed that ITK-SYK was not able to transform the pre-B cell line BaF/3. In agreement,
ITK-SYKCD19−Cre mice remained healthy until 30 weeks of age, while ITK-SYKCD4−Cre
mice already succumbed to T cell lymphoma at that age. On a molecular level it became
clear that whereas ITK-SYK is constitutively associated with lipid rafts in T cells, the
fusion kinase was not detected in lipid rafts isolated from B cells. This observation would
be in line with data gathered from JurkatE T cells, that membrane recruitment is neces-
sary for ITK-SYK mediated cell activation. Even though this observation could explain
why ITK-SYK does not affect B cell physiology, it still remains unclear why ITK-SYK
is selectively recruited into lipid rafts of T cell but not of B cells. Both TEC kinases
ITK and its B cell homolog BTK contain the N-terminally located PH domain, convey-
ing membrane recruitment upon PIP3 interaction [129, 12]. The PIP3 generating kinase
PI3K is expressed in both T cells [171] and B cells [102]. Thus, PIP3 in principle should
be available for PH domain mediated membrane recruitment of ITK-SYK in either cell
type. Yet, as differences are observed, it is hypothesized that ITK-SYK recruitment and
activity are dependent on a T cell characteristic signaling environment, and that selective
PH and TH domain mediated protein interactions are necessary for ITK-SYK activity.
The strong presence of endogenous ITK in lipid rafts of T cells might also hint at an
important involvement of ITK in conveying sustained ITK-SYK signaling. Additionally,
it could also be possible that ITK-SYK is exposed to a tighter negative regulatory control
in B cells than in T cells, preventing its full establishment at the B cell membrane.
An interesting observation concerning ITK-SYK membrane recruitment has been
presented by Dierks et al. [48]. The authors performed bone marrow transplantation
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experiments and demonstrated that recipient mice expressing the PH domain mutated
version of ITK-SYK showed an earlier onset of disease symptoms compared to recipients
expressing wildtype ITK-SYK. In order to understand the potential mechanism behind
this observation, the authors investigated the opposite scenario, namely enforced mem-
brane recruitment, and detect an increased phosphorylation of ITK-SYK on Tyr183. As
outlined in Section 6.3, Tyr183 corresponds to Tyr323 in the wildtype SYK molecule. It is
known, that Tyr323 acts as negative regulatory residue. Upon phosphorylation it recruits
the ubiquitin ligase Cbl and leads to proteasomal degradation of SYK [118]. Thus Dierks
et al. [48] argue that by loss of membrane localization, ITK-SYK escapes this regulatory
aspect. Interestingly, these observations might point to a first negative regulatory control
mechanism for ITK-SYK. Notably, these data might also have implications in composing
treatment strategies. Mere blocking of ITK-SYK membrane recruitment thus might lead
to a contrary effect as expected from in vitro observations. It remains open whether in a T
cell specific mouse model, expression of a cytoplasmically located ITK-SYK version would
result in the same observation as depicted in the bone marrow transplantation model.
Since no immediate effect of ITK-SYK on B cell development or B cell activation
was observed, ITK-SYKCD19−Cre mice were continued to be monitored in order to rule
out possible long term consequences of ITK-SYK activity on B cells. By doing so, quite
unexpectedly, the ITK-SYKCD19−Cre mouse model complemented the observations gath-
ered from the ITK-SYKCD4−Cre model, which does hold restrictions in its comparison to
the human disease scenario. Firstly, since Cre expression is controlled by the CD4 pro-
moter, deletion of the STOP cassette and subsequent ITK-SYK transcription occurs as
early as in DP thymocytes. Hence, for the vast majority of T cells, the onset of ITK-SYK
expression is not limited to the mature cell stage, as expected to be the case in human
PTCL. Secondly, ITK-SYK expression is engaged in over 80% of all T cells present in
ITK-SYKCD4−Cre mice. This is contrary to the human situation where the translocation
is a rare event expected to affect a single or only a few T cells. Therefore, it was interesting
to observe that ITK-SYKCD19−Cre mice eventually also developed a fatal form of PTCL.
They showed a comparable phenotyp to ITK-SYKCD4−Cre mice, except for a prolonged
latency. It is hypothesized that the rare event of sporadic CD19 promoter activity within
T cells results in a Cre mediated deletion of the STOP cassette, allowing T cell specific
ITK-SYK expression in ITK-SYKCD19−Cre mice. Analysis of TCRVβ chain distributions
indicated that expanded T cells originated from a single or only a few T cell clones.
Thus, sporadic ITK-SYK expression in single T cells drives PTCL development even in
ITK-SYKCD19−Cre mice, emphasizing the oncogenic nature of the fusion kinase. As dis-
cussed for the ITK-SYKCD4−Cre model, secondary oncogenic events might also contribute
to lymphoma development in ITK-SYKCD19−Cre . Whether ITK-SYK solely acts as tu-
mor initiator, or whether clonal expansion and tumor maintenance still rely on ITK-SYK
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activity is still a matter of investigation. First in vivo therapeutic approaches have been
performed by Dierks et al. [48] in a bone marrow transplantation model. The authors ob-
served a milder lymphoproliferative phenotype in recipient mice after treatment with the
SYK inhibitor curcumin. In agreement, the ITK-SYKKD mutant did not lead to disease
development at all. These data would support a scenario where not only disease initiation
but also disease development is at least partially dependent on ITK-SYK kinase activity.
Thus, blocking of SYK enzymatic activity might prove to be a sucessful therapeutic ap-
proach. The orally available SYK inhibitor R788 has already been investigated in clinical
trials for inflammatory autoimmune [196] and malignant diseases, such as B cell NHL
[58]. Currently, R788 is also under evaluation for treatment of refractory or relapse PTCL
(NIH, unpublished data).
Chapter 7
Summary and Outlook
Aberrant tyrosine kinase activity is known to be related to tumor development [17]. Often
enzymatic deregulation is a result of irregular chromosomal recombination, leading to the
generation of chimeric fusion tyrosine kinases [124]. The identification of recurrent translo-
cation events and the molecular understanding of new gene products has been especially
valuable in understanding the pathogenesis of hematopoietic malignancies [157]. Even if
restricted to a limited number of cases, translocations may point to a more commonly ap-
plied mechanism causing cell transformation. Recently, the translocation t(5;9)(q33;q22)
was identified as the first recurrent event in a subgroup of PTCL-NOS [178]. The translo-
cation affects the gene loci of two non receptor tyosine kinases, SYK and ITK, leading to
the expression of the fusion kinase ITK-SYK. Due to the aggressivness of PTCL and its
dismal treatment options, insights into tumor promoting events are needed.
To investigate in vivo consequences of ITK-SYK expression in a cell type specific
manner, and to clarify its oncogenic potential in PTCL development, conditional gene
targeting of the ROSA26 locus has been employed. In combination with in vitro analysis,
it was shown that ITK-SYK constitutively activates signaling pathways which are regu-
larly engaged upon TCR stimulation. Phosphorylation of key TCR signaling molecules
such as LAT, SLP-76, and PLCγ1 were observed. Additional activation of AKT, as well
as the MAPK proteins p38 and ERK1/2 was seen. In vitro ITK-SYK expression resulted
in IL-2 production and CD69 expression, both being classical signs of early T cell acti-
vation. Notably, ITK-SYK was constitutively recruited into T cell lipid rafts. A general
enrichment of tyrosine phosphorylated raft proteins was also observed. Since ITK-SYK
structurally lacks dimerization domains to mediate self activation, constitutive membrane
association could present a common activation strategy for a new set of fusion tyrosine
kinases. Indeed, mutational in vitro analysis demonstrated that ITK-SYK induced T cell
activation is dependent on PH domain mediated membrane recruitment as well as on
its functional kinase activity. However, since a contradictory role of ITK-SYK membrane
localisation has been ascertained in bone marrow transplantation experiments [48], the
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inconsistency with the here presented in vitro data necessitates further investigation.
In order to answer the question whether ITK-SYK can also drive T cell transfor-
mation, longterm in vivo investigations were performed. Indeed, ITK-SYKCD4−Cre mice
developed highly malignant PTCLs with 100% penetrance. Flow cytometric as well as his-
tological analysis confirmed expansion of neoplastic T cells, and showed their aggressive
nature. Infiltrations were detected in all analyzed organs, lymphoid as well as non lym-
phoid. Finally, clonally expanded T cells were transplantable, and induced a similar disease
phenotype in recipient mice. Together, the described clinical and pathological features of
ITK-SYKCD4−Cre mice were reminiscient of human PTCL [38]. Interestingly, ITK-SYK
selectively activated T cells, yet not B cells as was observed in ITK-SYKCD19−Cre . Dif-
ferent outcomes may originate from ITK-SYK being constitutively recruited into lipid
rafts of T cells but not B cells. The reason for this behavior, however, is still unknow.
Even if ITK-SYKCD19−Cre mice did not show a B cell phenotype, it was observed that
sporadic ITK-SYK expression in single T cells, eventually also led to the development
of fatal PTCL in these mice. This observation presumably stems from rare CD19 pro-
moter activity occuring in few T cells. Cre expression results in the deletion of the
STOP cassette, ITK-SYK expressing T cells expand and cause PTCL to occur. Thus,
the ITK-SYKCD19−Cre model strongly supports that ITK-SYK can drive T cell oncoge-
nesis. The fact that ITK-SYKCD4−Cre as well as ITK-SYKCD19−Cre mice showed clonal
T cell outgrowth, suggests that in both models cooperating events contribute to the pro-
liferative advantage of ITK-SYK expressing T cells. Currently, it still remains a matter
of investigation whether constitutive ITK-SYK signaling is predominantly responsible for
tumor initiation or whether it is also essential for disease maintenance. The aspect of
so-called oncogene addiction [187] will have critical implications on the development of
sucessful treatment strategies. Insights into this matter could be obtained by treating
affected mice with the orally available SYK inhibitor R788, which has already shown
potential in treating B cell malignancies [58] and rheumatoid arthritis [196].
Concludingly, the work at hand presents first conditional mouse models of ITK-SYK
driven PTCL development and suggests that constitutively enforced AgR signals are in
principle able to induce oncogenesis in an in vivo setting. Since aberrant AgR signaling
is frequently observed in human lymphoid malignancies [98, 40], it will be interesting to
see whether deregulated TCR signaling in general or abnormal SYK activity specifically
is a common mechanism found in PTCL pathogenesis. Concerning later aspect, Feld-
man et al. [55] demonstrated that over 90% of analyzed PTCL-NOS cases showed SYK
overexpression. Thus, while the translocation t(5;9)(33;22) affects a limited percentage
of PTCL-NOS cases, aberrant SYK activity might indeed be a common driver in PTCL
pathogenesis. Since ITK-SYK induces activation of various signaling components the here
presented mouse models will be of use in understanding the role of individual signaling
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molecules in ITK-SYK mediated oncogenesis. The question can be approached on a ge-
netic basis by crossing ITK-SYK transgenic mice with knockout mouse strains deficient
for the signaling molecule of interest. In combination with in vivo inibitor experiments
these investigations will be helpful in identifying signaling molecules or pathway showing
the most potential as candidates for therapeutic intervention.
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